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1. Introduction 
This thesis deals with the interaction between the neonatal Fc receptor and 
immunoglobulin G antibodies. The introduction gives a brief summary on antibodies, 
the neonatal Fc receptor and the model antibodies used in this work. 
1.1. Antibodies 
In 1890, Emil von Behring and Shibasaburo Kitasato first described the use of 
antitoxins in serum therapy. They suggested that antibodies could specifically 
eliminate diphtheria and tetanus toxins (Behring and Kitasato 1890). This finding 
was the key to establish an effective vaccination against diphtheria. Today, 
diphtheria vaccination is available to almost every child.  
Since that time, antibodies have been studied and characterized in detail. The first 
therapeutic antibody was a murine monoclonal antibody (mAb) named Muromonab-
CD3 in 1986 which had severe side effects (Perens et al. 2007). The development 
from murine to chimeric and later to humanized and human antibodies reduced the 
occurrence of side effects (Reff and Heard 2001). Furthermore the indication areas 
grew steadily in the last years, including cancer, autoimmune, viral, inflammatory 
and ophthalmic diseases. However, the development of new applications and 
approaches for antibodies will continue in the next years.  
1.1.1. Antibody structure 
Antibodies are members of the immunoglobulin (Ig) family (Campbell and Reece 
2006). They are classified by their function and pharmacokinetic properties into 
five isotypes: immunoglobulin alpha (IgA), delta (IgD), epsilon (IgE), gamma (IgG) 
and my (IgM) (Lobo et al. 2004). In mammals, antibodies of the IgG type constitute 
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one of the immune system’s major components for the defense against pathogens 
such as bacteria, viruses and fungi. They are secreted by plasma B cells and represent 
approximately 75% of serum immunoglobulins in healthy humans (Janeway et al. 
2001).  
Human IgG (~150 kDa) is a protein consisting of four polypeptide chains, including 
two identical heavy chains (HC) and two identical light chains (LC) assembled by 
disulfide bonds (Figure 1-1) (Campbell and Reece 2006). 
 
 
Figure 1-1: Schematical IgG structure 
IgG consists of two identical heavy (HCs) and light chains (LCs) which are covalently linked 
by disulfide bonds. The HC consists of three constant domains (CH1, CH2, CH3) and a 
variable domain (VH). The LC consists of one constant domain (CL) and a single variable 
domain (VL). The antigen binding fragment (Fab) consists of the LC and of the CH1 and VH 
domains of the HC. The variable region of the Fab (Fv) consists of the VH and VL domains 
and includes the complementarity determining regions (CDRs). The crystallizable fragment 
(Fc) comprises the CH2 and CH3 domains.  
IgGs are divided into four subclasses according to their HC sequence (Janeway et al. 
2001; Lobo et al. 2004): IgG1, IgG2, IgG3 and IgG4. Most therapeutic antibodies 
belong to the IgG-isotype and the IgG1 subclass, therefore this work focusses on 
IgG1 as antibody-isotype. Each HC has a molecular weight (MW) of about 50 kDa 
and consists of four domains: Three domains in the constant region CH1, CH2, CH3 
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and a single domain in the variable domain VH. CH1 and CH2 are connected to each 
other via the hinge region that is responsible for the high structural flexibility of IgGs 
(Janeway et al. 2001; Khawli et al. 2010; Reff and Heard 2001).  
Table 1-1: Properties of human IgG subclasses 
The IgG subclasses are named in order of their serum abundance, starting with IgG1 as most 
abundant. Data reported by Janeway et al. (2001). 
 IgG1 IgG2 IgG3 IgG4 
Mean serum level [mg/mL] 9 3 1 0.5 
Serum half-life [d] 21 20 7 21 
 
IgGs can be further classified by their LC sequence into kappa (κ) and lambda (λ) 
(Janeway et al. 2001). Each LC has a MW of about 25 kDa and consists of two 
domains: the constant domain CL and the variable domain VL. 
Antibodies have two functional domains, namely the antigen binding fragment (Fab) 
and the crystallizable fragment (Fc). The constant domains CH2 and CH3 form the Fc 
region. The Fc region interacts with effector molecules such as complement proteins 
and Fc receptors (FcRs) (Jefferis 2009; Raghavan and Bjorkman 1996; Reff and 
Heard 2001). 
The Fab fragment consists of the two LC and the two HC domains CH1 and VH and 
is responsible for recognizing and binding the antigen. The variable region of the 
Fab (Fv) contains the VH and VL domains and includes the complementarity 
determining regions (CDRs) that are responsible for highly specific antigen binding 
(Mould and Green 2010). Each antibody has two Fab regions and can therefore bind 
two antigens simultaneously (Reff and Heard 2001). 
1.1.2. Antibody function 
IgGs are major components of the immune system. The Fab region comprises the 
antigen binding site and is responsible for the ability of the IgG to specifically 
recognize diverse antigens. The high specificity is due to the CDRs in the Fab region 
which recognize defined antigen structures, the so-called epitopes (Campbell and 
Reece 2006). 
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The Fc part of an IgG does not bind to antigens but couples the antibody to immune 
effector pathways to target and eliminate pathogens and foreign molecules:  
 Interaction with the C1q-component of the complement system leads to 
phagocytosis and complement dependent cytotoxicity (CDC) (Jefferis 2009; 
Montano and Morrison 2002). 
 Binding to Fcɣ receptors (FcɣRs) leads to phagocytosis and antibody 
dependent cellular cytotoxicity (ADCC) (Keizer et al. 2010; Montano and 
Morrison 2002; Mould and Green 2010; Reff and Heard 2001). 
 Interaction with neonatal Fc receptor (FcRn) influences IgG homeostasis 
resulting in prolonged serum half-life (Lobo et al. 2004; Mould and Green 
2010; Roopenian and Akilesh 2007). 
1.1.3. Therapeutic antibodies 
The generation of the first monoclonal antibody by hybridoma technology in 1975 
was one of the starting points for the development of therapeutic antibodies (Köhler 
and Milstein 1975). 
Therapeutic antibodies in modern medicine play a major role in the treatment of 
various diseases, e.g. cancer and autoimmune diseases. The importance of 
therapeutic antibodies to the drug market increases continuously. To date, more than 
30 monoclonal antibodies have been approved by the US Food and Drug 
Administration (FDA) and it is estimated that over 300 other antibodies are currently 
in development (Benson et al. 2011; Yamada 2011). Thus, the number of therapeutic 
antibodies is going to increase in the following years. It is therefore important to 
understand pharmacokinetic (PK) aspects of these potentially life-saving protein 
drugs. 
Therapeutic antibodies are mainly administered parenterally via intravenous (i.v.) or 
subcutaneous (s.c.) application due to their large molecular size, high polarity and 
gastric instability (Tabrizi et al. 2006). The PK profile of therapeutic antibodies is 
described by absorption (except for i.v. administration), distribution and elimination 
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processes and is on a molecular level mainly dependent on the target antigen and on 
the antibody structure itself (Ternant and Paintaud 2005; Wang et al. 2008). 
Antibodies directed against soluble targets (e.g. cytokines) are internalized via fluid-
phase endocytosis into cells, where the target is degraded. These antibodies in 
general show a dose-proportional behavior with linear clearance because the 
clearance is limited to catabolic processes (Mould and Green 2010). 
In contrast, antibodies directed against targets on cell surfaces can also be 
internalized via receptor-mediated endocytosis and may therefore show target-
mediated clearance (Wang et al. 2008). Target-mediated clearance is usually a 
saturable process; uptake and elimination of the therapeutics are dependent on the 
expression of the target and the antibody dose. Antibodies that undergo target-
mediated clearance show therefore typically a nonlinear clearance (Keizer et al. 
2010).  
Besides the influence of the target antigen, the antibody structure itself can also 
influence PK. The charge of an antibody for example can influence PK by affecting 
the electrostatic interaction between the antibody and negatively charged groups on 
the surface of cells (Khawli et al. 2002). 
Furthermore antibodies having the tendency to form aggregates can show an altered 
PK profile. The formation of aggregates is often caused by hydrophobic regions of 
an antibody and can impact immunogenicity, which is defined as the ability to 
provoke an immune response (Putnam et al. 2010). In the course of an immune 
response anti-drug antibodies (ADAs) can be formed against the therapeutic antibody 
which in turn influence PK by formation of drug/ADA immune complexes that 
induce a quick elimination (Brinks et al. 2011; Pendley et al. 2003). 
Finally, structural heterogeneities in the Fc region of an antibody can alter the 
interaction with Fc receptors and consequently influence PK. For example, 
differences in the glycosylation pattern in the Fc region can affect binding to 
Fcɣ receptors and complement proteins and subsequently influence PK by altered 
CDC or ADCC. However, of particular importance is the Fc region of an IgG 
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antibody, because of its interaction with the neonatal Fc receptor. Human IgGs of 
subclasses 1, 2, and 4 have a prolonged half-life of up to 21 days which is mediated 
by the interaction with FcRn (Chaudhury et al. 2003; Ghetie and Ward 2000). The 
long serum persistence and the high specificity of IgGs are the main reasons why 
IgGs are widely used as therapeutic proteins. 
FcRn 
7 
 
1.2. FcRn 
The neonatal Fc receptor was first described by Brambell et al. in 1964 and is 
therefore also known as the Brambell-receptor (Brambell et al. 1964; Junghans 
1997). The Fc receptor was named neonatal due to its initially identified function of 
transporting maternal IgG to the fetus and thereby building the humoral immunity of 
the fetus (Brambell 1966). Today, it is known that FcRn is also expressed in adults 
and has several important functions (1.2.3) but for historical reasons it is still called 
the neonatal Fc receptor. 
1.2.1. FcRn structure 
Human FcRn is a heterodimeric glycoprotein consisting of a 42-44 kDa class I major 
histocompatibility complex (MHC I)-like heavy chain (α-FcRn) and a non-covalently 
associated 12 kDa β2 microglobulin (β2m) light chain (Kuo et al. 2010; Low and 
Mezo 2009; Rodewald 1976; Simister and Rees 1985). The heavy chain is 
membrane-bound and is composed of three extracellular domains (α1, α2, α3), a single 
transmembrane domain and a short cytoplasmic sequence domain (Bjorkman and 
Parham 1990; Simister and Mostov 1989). The α domains, especially the α2 domain, 
represent the binding site to IgG (Giragossian et al. 2013).  
Mouse, rat and monkey FcRn amino acid sequences share 66 %, 65 % and 95 % 
sequence identity with human FcRn, respectively (Giragossian et al. 2013). 
1.2.2. FcRn expression 
In adults, FcRn is primarily expressed in vascular endothelial cells or the 
reticuloendothelial system (RES) (Mould and Green 2010). More precisely, FcRn is 
mainly expressed by endothelial cells of muscle, skin, liver, spleen, kidney, blood-
brain barrier, blood-ocular barrier and circulating monocytes (Akilesh et al. 2007; 
Blumberg et al. 1995; Borvak et al. 1998; Cianga et al. 2011; Kim et al. 2008; 
Schlachetzki et al. 2002). In most cell types the steady state cell-surface expression 
levels of FcRn are low (Ward and Ober 2009). 
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1.2.3. FcRn function 
FcRn plays a major role in several processes: 
 in IgG and albumin homeostasis 
 in passive humoral immunity 
 in regulating antigen presentation 
 in regulating IgG concentration in brain and kidney 
The key feature of the FcRn-IgG interaction and also of the FcRn-albumin 
interaction is pH-dependent binding (Chaudhury et al. 2003; Datta-Mannan et al. 
2007), although IgG and albumin have independent binding sites on the FcRn (Kim 
et al. 2006).  
1.2.3.1. FcRn-IgG binding mechanism 
The cognate FcRn binding site is located at the CH2-CH3 interface of an IgG. The 
FcRn-IgG interaction occurs in a 1:2 stoichiometry, with one IgG binding to two 
FcRn molecules via its two heavy chains (Figure 1-2) (Huber et al. 1993; Sanchez et 
al. 1999). 
 
 
Figure 1-2: FcRn-IgG interaction 
The heterodimeric FcRn molecule is illustrated as MHC I-like HC in red and β2m in yellow. 
The cognate FcRn binding site is at the CH2-CH3 domain of the IgG (green). 
The interaction between IgG and FcRn is strictly pH-dependent, showing nanomolar 
affinity at endosomal pH of 5-6 and negligible binding at physiological pH of 7.4 
(Goebl et al. 2008; Ober et al. 2004a; Ober et al. 2004b). Responsible for this pH-
FcRn 
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dependent binding are histidine residues located at the CH2-CH3 interface of the IgG 
which interact with acidic residues on the FcRn surface at acidic pH (Raghavan et al. 
1994). Increasing pH values result in deprotonation of the histidine residues of the 
IgG and in dissociation of the FcRn-IgG complex. In addition to this ionic 
interaction, there are hydrophobic interactions between isoleucine residues of the IgG 
and tryptophan residues of the FcRn (Raghavan et al. 1995; Roopenian and Akilesh 
2007). 
1.2.3.2. Regulating IgG homeostasis 
Human IgGs of subclasses 1, 2 and 4 have an average serum half-life of 21 days, 
which is longer than that of any other known serum protein (Waldmann and Strober 
1969). This long half-life is predominantly mediated by the interaction of IgGs with 
FcRn (Chaudhury et al. 2003; Ghetie and Ward 2000). The underlying mechanism is 
illustrated in Figure 1-3: IgGs are subject to unspecific pinocytosis by various cell 
types (Akilesh et al. 2007; Montoyo et al. 2009). Afterwards IgGs encounter and 
bind FcRn in the acidic endosome at a pH of 5-6 (Rodewald 1976; Roopenian and 
Akilesh 2007). The endosome is divided into two parts, either containing molecules 
bound to FcRn or molecules not bound to FcRn. IgGs bound to FcRn are transported 
to the cell surface and are released in the extracellular space at physiological pH of 
7.4, thereby protecting IgGs from lysosomal degradation (Ghetie and Ward 2000; 
Raghavan and Bjorkman 1996). Afterwards FcRn is transported back in the cell 
following exocytotic fusion with the cell membrane, which in turn results in low 
steady-state levels of FcRn on the plasma membrane (Ghetie et al. 1996; Ober et al. 
2004b). Molecules that are not bound to FcRn in the endosome, like weakly 
interacting antibodies, antigens or serum proteins, are degraded in the lysosomes. 
The strict pH-dependent bind-and-release mechanism is critical for IgG-recycling 
and any deviation of the binding characteristics at different pHs may strongly 
influence circulation half-lives of IgGs (Schlothauer et al. 2013; Vaccaro et al. 2005).  
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Figure 1-3: IgG-recycling mechanism  
IgGs are subject to unspecific pinocytosis. Afterwards IgGs encounter and bind FcRn in the 
acidic endosome at a pH of 5-6 and are subsequently transported back to the cell surface. 
Finally, IgGs are released in the extracellular space at physiological pH of 7.4. In contrast, 
antigens, serum proteins and unbound antibodies are degraded in the lysosome. The figure 
was modified from Roopenian and Akilesh (2007). 
Although IgG3 also binds to FcRn, IgG3 has a serum half-life of only 7 days. This 
can be explained by the intracellular competition between IgG1 and IgG3 that 
inhibits FcRn-mediated IgG3-recycling (Stapleton et al. 2011). 
1.2.3.3. Passive humoral immunity 
FcRn transfers IgG from mother to fetus via transcytosis across a polarized cell layer. 
The underlying mechanism differs between rodents and humans. In rodents, FcRn 
transports maternally derived IgG in ingested milk across the epithelial-cell layer of 
the proximal small intestine (Jones and Waldmann 1972). In humans on the other 
hand, FcRn transports maternal IgG across the placenta to the fetus. Here, FcRn is 
expressed by syncytiotrophoblasts, where it transports maternal IgG to the fetal 
capillaries of the placental villi (Leach et al. 1996; Simister et al. 1996). 
FcRn 
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1.2.3.4. Regulating antigen presentation 
FcRn is also expressed in antigen presenting cells (APCs) like monocytes, 
macrophages and dendritic cells (Zhu et al. 2001). In these cells, FcRn regulates IgG 
homeostasis (Akilesh et al. 2007) but it can also enhance antigen presentation by 
directing antigen-IgG immune complexes into lysosomes in dendritic cells (Qiao et 
al. 2008). This results in the higher phagocytic activity of monocytes relative to 
natural killer (NK) cells that do not express FcRn (Ward and Ober 2009). 
1.2.3.5. Regulating IgG concentration in specialized cell types 
FcRn is also expressed in several specialized cell types like in the blood brain barrier, 
the kidney and multiple ocular tissues. The exact functions of FcRn at the blood-
ocular barrier, cornea or retina remain currently unknown (Kim et al. 2008). 
FcRn is expressed in brain microvasculature and in the choroid plexus epithelium at 
the blood–brain barrier (BBB) (Schlachetzki et al. 2002). The blood–brain barrier 
prevents the passive diffusion of macromolecules, like IgG, into the central nervous 
system (CNS) (Roopenian and Akilesh 2007). In response to inflammatory 
mediators, like tumor-necrosis factor alpha (TNFα), the blood–brain barrier can open 
transiently (Ballabh et al. 2004). In these situations, IgG would flood into the CNS 
down its steep concentration gradient and FcRn probably mediates reverse 
transcytosis of IgG from the CNS back into the circulation to maintain low levels of 
potentially inflammatory antibodies in the CNS (Roopenian and Akilesh 2007; Ward 
and Ober 2009). 
The kidney functions as plasma filter using a size-selective barrier at the level of the 
glomeruli. Macromolecules of 70 kDa and larger cannot enter the barrier, whereas 
smaller molecules are excreted in the primary urine. IgG and albumin are both serum 
proteins with high molecular weight and are therefore excluded from the primary 
urine (Akilesh et al. 2007). These serum proteins could clog the kidney filter if they 
were not efficiently removed (Ward and Ober 2009). FcRn is expressed by epithelial 
cells of the glomerulus (podocytes) and transports deposited IgG from the basolateral 
surface of the podocyte into the primary urine of the glomerulus via transcytosis 
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(Haymann et al. 2000). FcRn is also expressed by epithelial cells of the proximal 
convoluted tubule to transcytoses IgG back into the systemic circulation (Kobayashi 
et al. 2002).  
1.2.4. Human FcRn transgenic mouse model 
Pharmacokinetics of therapeutic antibodies is often analyzed in mice during 
preclinical tests, before usage in humans (Ober et al. 2001). Human PK cannot be 
fully reflected by conventional mouse models, because binding of FcRn and IgG is a 
species-specific interaction (Roopenian et al. 2010). Murine FcRn binds IgG of 
several species, e.g. human, mouse, rabbit, guinea pig, bovine, sheep and rat IgG 
(Ober et al. 2001). On the contrary, human FcRn only binds human, rabbit and 
guinea pig IgG but not mouse IgG (Vaccaro et al. 2006; Zhou et al. 2005). 
Furthermore conventional mouse model systems do not reliably describe the 
pharmacokinetics of humanized antibodies and Fc-fusion proteins, because these 
antibodies have an abnormally high affinity for mouse FcRn, resulting in an 
artificially prolonged serum persistence (Ober et al. 2001; Petkova et al. 2006; 
Ternant and Paintaud 2005). These species-specific differences in affinity occur 
probably due to different glycosylation patterns in humans and rodents (Kuo et al. 
2009). 
To overcome the limitation in the conventional rodent model, the human FcRn 
transgenic mouse model is often used. This model mimics the interaction between 
human FcRn and human IgGs and is therefore an appropriate model to gain 
information about the prospective PK profile of human IgGs in humans (Roopenian 
et al. 2010). IgG elimination is dependent on the FcRn expression level, therefore the 
FcRn expression level is higher in homozygous mice than in heterozygous mice. 
Furthermore Roopenian et al. (2010) described three transgenic mouse lines that 
express different levels of FcRn: FcRn knockout mice (mFcRn -/-) expressing no 
FcRn, the human FcRn transgenic mice Tg276 and Tg32 expressing moderate and 
high levels of FcRn, respectively. To investigate PK differences of antibodies the use 
of heterozygous human FcRn transgenic mice Tg276 (B6.Cg-
<tm1Dcr>Tg(FCGRT)276Dcr) is best suited (Roopenian et al. 2010). 
FcRn 
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Human FcRn transgenic mice lack endogenous mouse FcRn and instead express 
human FcRn (Petkova et al. 2006). As mouse IgG has only little affinity to human 
FcRn resulting in a fast clearance of mouse IgG, these mice show immunodeficiency. 
An accurate animal husbandry minimizes the risk of bacterial infections (Qiao et al. 
2008). 
An even more significant alternative to the FcRn transgenic mouse model would be 
the cynomolgus monkey model, but access to this model is limited due to ethical and 
cost reasons (Ward and Ober 2009). 
1.2.5. IgG-engineering 
FcRn plays a key role in regulating IgG homeostasis, therefore modulating the 
interaction between IgG and FcRn through protein engineering is an attractive 
method to modulate target-independent PK properties (Ghetie et al. 1997; Shields et 
al. 2001). In some cases antibodies with prolonged half-life are desired to lower the 
application dose or to reduce the application frequency of therapeutic antibodies in 
order to improve patient convenience and patient compliance (Hinton et al. 2004; 
Hinton et al. 2006). In other cases, antibodies with reduced half-life in the blood 
circulation are desired. For example, drugs for intravitreal application should 
preferentially have a long half-life in the eye and a short half-life in the circulation of 
the patient. Such antibodies could then have the advantage of increased exposure to a 
disease site, e.g. in the eye.  
Different mutations that influence FcRn binding and therewith the half-life in the 
blood circulation are known. 
FcRn binds to the Fc region at the CH2-CH3 domains of IgG, therefore modifications 
in that binding area can directly influence FcRn-IgG interaction (Raghavan et al. 
1995; Roopenian et al. 2010; Roopenian and Akilesh 2007). Specific manipulations 
of the Fc region are known to affect PK characteristics by altering the interaction 
between Fc region and FcRn especially at pH 6.0 and such modifications have been 
used to design therapeutic antibodies with specific PK properties (Dall'Acqua et al. 
2006; Petkova et al. 2006).  
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A triple mutation M252Y/S254T/T256E (YTE) in the Fc region of an antibody 
against respiratory syncytial virus (MEDI-524) resulted in a 10-fold increase in its 
FcRn affinity at pH 6.0 and subsequently in a nearly 4-fold increase in serum half-
life in cynomolgus monkeys (Petkova et al. 2006; Yeung et al. 2009). 
A single mutation (N434A) in the Fc region resulted in a 4-fold improvement in 
pH 6.0 binding and a 2-fold decrease in clearance in cynomolgus monkeys compared 
to the wild type antibody (Yeung et al. 2009).  
Importantly, in another case, a single mutation (N434W) increased pH 6.0 binding 
80-fold but did not result in prolonged half-life compared to the wild type antibody. 
This PK behavior was explained by the simultaneously improved binding to FcRn at 
pH 7.4, highlighting the importance of preserving the efficient pH-dependent release 
of IgGs at pH 7.4 when engineering antibodies with increased terminal half-lives 
(Suzuki et al. 2010; Wang et al. 2011). 
In addition to the specific interaction of the Fc region with FcRn, the Fab regions 
have also been suggested to contribute to the FcRn-IgG interaction (Igawa et al. 
2010; Schlothauer et al. 2013; Wang et al. 2011).  
Wang et al. (2011) reported that IgGs with different target specificities and Fab 
regions but identical Fc sequences can have different FcRn affinities. Fab-mediated 
residual binding at near physiological pH was correlated with the pharmacokinetic 
properties of a set of therapeutic antibodies indicating that IgGs with excessive 
binding to FcRn at pH 7.3 suffer from reduced terminal half-lives. 
Recently, Schlothauer et al. (2013) have described a novel pH-gradient FcRn affinity 
chromatography method that closely mimics physiological conditions for the 
dissociation between FcRn and IgG. Furthermore, they showed that IgGs with 
identical Fc regions differ in their dissociation from FcRn in vitro, thereby indicating 
the influence of the Fab region on FcRn-IgG interaction. 
However, the underlying mechanism of the distal Fab region’s influence on FcRn 
binding is hitherto only poorly understood. A deep understanding of the FcRn-IgG 
interaction is of high interest, especially in drug development and FcRn-dependent 
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antibody-engineering. Therefore the Fab influence on FcRn-IgG interaction needs to 
be further investigated. 
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1.3. Antibody model system 
For systematic analysis of the Fab influence on FcRn-IgG interaction, an appropriate 
antibody model system is needed. The model antibodies should have similar Fc 
regions, but differences in their terminal half-lives. Furthermore, model antibodies 
should have identical target specificities to exclude target-dependent effects on PK. 
Therefore, Briakinumab (Ozespa™) and Ustekinumab (Stelara™) were used as a 
model system to systematically investigate the influencing factors of the Fab region 
on FcRn-mediated IgG homeostasis. 
1.3.1. Briakinumab and Ustekinumab 
Briakinumab and Ustekinumab are two therapeutic antibodies both directed against 
soluble interleukin 12 (IL-12) and interleukin 23 (IL-23). IL-12 and IL-23 are 
heterodimeric, pro-inflammatory cytokines consisting of p40/p35 subunits and of 
p40/p19 subunits, respectively (Elliott et al. 2009; Gandhi et al. 2010). Briakinumab 
and Ustekinumab specifically bind to the shared p40-subunit of IL-12 and IL-23 and 
prevent them from binding to their cell surface receptor complexes, thereby blocking 
inflammatory pathways (Ding et al. 2008; Kurzeja et al. 2011). Briakinumab and 
Ustekinumab are not cross-reactive to mouse IL-12 and IL-23 (Luo et al. 2010; 
Traczewski and Rudnicka 2012), thus target-mediated clearance can be excluded 
when performing a PK study in mice. 
Briakinumab, developed by Abbott, was intended to be used for the treatment of 
moderate to severe chronic plaque psoriasis in adults who failed to respond to, or 
who have a contraindication to, or are intolerant to other systemic therapies including 
ciclosporin, methotrexate and psoralen ultraviolet A (PUVA). In January 2011, 
Abbott withdrew its application for marketing authorization due to occurrence of 
major adverse cardiovascular events (MACEs) after Briakinumab treatment 
(European Medicines Agency 2011). The initial dose for Briakinumab was 200 mg 
as s.c. application. Followed by injection of 200 mg after 4 weeks and afterwards of 
100 mg every 4 weeks (Inzinger et al. 2012). 
Ustekinumab, developed by Centocor Ortho Biotech Inc., is indicated in the EU for 
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use in adults with moderate to severe plaque psoriasis who have not responded to or 
cannot use other systemic treatments for psoriasis, such as ciclosporin, methotrexate 
or PUVA. Furthermore it is used to treat adults with active psoriatic arthritis, when 
the condition has not responded well enough to other treatments called disease-
modifying antirheumatic drugs (European Medicines Agency 2009b). Ustekinumab 
is administered as s.c. injection at a concentration of 45 mg. The second dose is 
given 4 weeks after the initial dose and afterwards every 12 weeks. The dose is 
adjusted to 90 mg for patients weighing more than 100 kg (Weber and Keam 2009). 
Briakinumab and Ustekinumab are two fully human monoclonal IgG1 antibodies 
(Lima et al. 2009; Weger and Weger 2010). Both antibodies have nearly identical Fc 
domains with minor differences in several allotype-specific amino acids in this 
region.  
Briakinumab is an IgG1λ antibody with variable heavy and light chain domains of the 
VH3 and Vλ1 germline families. Ustekinumab is an IgG1κ antibody with variable 
heavy and light chain domains of the VH5 and Vκ1D germline families, respectively. 
Briakinumab has an estimated bioavailability of approximately 42% after single dose 
s.c. application (Lima et al. 2009). Maximum serum concentrations (cmax) were 
achieved after 3-4 days (Tmax) (Gottlieb et al. 2007; Weber and Keam 2009). 
Ustekinumab had an estimated bioavailability of 57.2% after single s.c. dose and a 
slow absorption with Tmax of approximately 12 days (Zhu et al. 2009). Interestingly, 
Ustekinumab has a median terminal half-life of 22-24 days (Kauffman et al. 2004), 
whereas Briakinumab has a terminal half-life of only 8-9 days after i.v. 
administration (Lima et al. 2009).  
In summary, Briakinumab and Ustekinumab have the same target specificity and 
nearly identical Fc sequences but show different terminal half-lives in humans. 
Therefore these antibodies were chosen to elucidate the role of the Fab region on 
FcRn-dependent PK. 
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1.3.2. Bevacizumab and Bevacizumab-variant 
To confirm the results of the Briakinumab-Ustekinumab model system, a second 
model system with Bevacizumab (Avastin®) and a specifically engineered variant of 
Bevacizumab was used. 
Bevacizumab is a humanized monoclonal IgG1 antibody with variable kappa light 
chains directed against the vascular endothelial growth factor (VEGF) (Braghiroli et 
al. 2012; European Medicines Agency 2009a). VEGF is a signal protein that 
stimulates vasculogenesis and angiogenesis. Bevacizumab binds to VEGF and slows 
the growth of new blood vessels, thereby inhibiting the blood supply to cancer cells 
and subsequently inhibiting tumor growth and proliferation (European Medicines 
Agency 2009a).  
Bevacizumab, developed by Hoffmann-La Roche, is used for the treatment of several 
cancer types including for example cancer of the colon or rectum, metastatic breast 
cancer and/or advanced or metastatic kidney cancer (Braghiroli et al. 2012; Rosen 
2005). The recommended dose is between 5 and 15 mg/kg of body weight every two 
or three weeks, depending on the type of cancer being treated. Bevacizumab is 
administered as an i.v. infusion (European Medicines Agency 2009a). 
Bevacizumab has a reported terminal half-life of up to 21 days in humans and of 
about 6.8 days in mice (Lin et al. 1999; Vieira and Rajewsky 1988). 
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1.4. Aim of the thesis 
In recent years the importance of therapeutic antibodies has been rapidly increasing. 
Therefore it is necessary to understand pharmacokinetic and pharmacodynamic 
aspects of these protein drugs. Due to their large molecular size, antibodies are 
expected to show poor bioavailability following oral administration. In addition, 
antibodies can undergo denaturation due to the acidic pH of the stomach, and 
proteolytic degradation within the stomach and intestine (Tabrizi et al. 2006). Thus, 
antibodies are administered parenterally via i.v. or s.c. application which is 
inconvenient for patients and can reduce the patient compliance. Therefore 
antibodies with prolonged half-life are desired to lower the application dose or 
reduce the application frequency of the therapeutic antibodies. In other cases, 
antibodies with reduced half-life in the blood circulation are desired, for example 
antibodies used for intravitreal application. These antibodies should have a high 
concentration at the desired site of action, which is inside the eye, but a low 
concentration in circulation to reduce systemic side effects. In conclusion, 
modulating antibody PK to reduce or prolong terminal half-lives in early 
development stages is of high interest.  
The IgG interaction with FcRn is important in regulating IgG homeostasis, therefore 
modulating the interaction between IgG and FcRn through protein engineering is an 
attractive method for modulating target-independent PK properties. Specific 
manipulations of the Fc region are known to affect PK characteristics by altering the 
interaction between Fc region and FcRn, especially at pH 6.0, and have been used to 
design therapeutic antibodies with specific PK properties (Dall'Acqua et al. 2006). 
However, antibodies having the same Fc regions do not simply have to have a similar 
PK profile. An additional contribution of the Fab region to FcRn binding has been 
reported, but the underlying mechanism remained unknown (Schlothauer et al. 2013; 
Wang et al. 2011; Zalevsky et al. 2010).  
The aim of this thesis was to elucidate the influencing structural element of the Fab 
region and the underlying mechanism that influences FcRn-IgG interactions and 
FcRn-dependent PK. Two IgG1 antibodies, Briakinumab and Ustekinumab, that 
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have similar Fc regions but very different terminal half-lives in human, were 
therefore chosen as model system. Systematically engineered variants of 
Briakinumab and Ustekinumab with cross-over exchanges and modified charge 
distribution in the Fab region were produced to localize the influencing structural 
element of the Fab region and to analyze if the interaction was charge-mediated. 
These antibodies were biochemically and functionally characterized to confirm that 
antibodies were produced correctly and to look for reasons explaining differences in 
PK. The interaction with FcRn was studied to elucidate the contribution of the FcRn-
IgG interaction on PK. Afterwards, antibodies differing in their FcRn-IgG interaction 
were analyzed in in vivo PK studies. Finally, the transferability of the previous 
results to a second model antibody system was tested. 
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2. Material 
In the following chapter all reagents, chemicals, kits, mice strains and instruments 
used in this work are listed. 
2.1. Reagents and chemicals 
The reagents and chemicals used in this work are listed in Table 2-1: 
Table 2-1: Reagents and chemicals 
 
Description Provider 
ABTS Roche Diagnostics GmbH, Mannheim, 
Germany 
10mM sodium acetate, pH 4.5 GE Healthcare, United Kingdom 
DTT Sigma-Aldrich Chemie GmbH, 
Germany 
HBS P+, pH 7.4 GE Healthcare, United Kingdom 
HCl (37%, Ph.Eur.) Carl Roth GmbH, Germany 
Histidine (≥ 98.5%, Ph.Eur.) 
 
Carl Roth GmbH, Germany 
H3PO4 (85%, Ph.Eur.) 
 
Carl Roth GmbH, Germany 
Isoflurane CP-Pharma GmbH, Germany 
KCl (≥ 99%, Ph.Eur.) 
 
 
Carl Roth GmbH, Germany 
KH2PO4 (≥ 98%, Ph.Eur.) 
 
 
Carl Roth GmbH, Germany 
MES (≥ 99%, Ph.Eur.) 
 
 
Carl Roth GmbH, Germany 
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Methyl cellulose Proteinsimple, USA 
Mouse Pool Serum (C57BL/6J mice) Roche Diagnostics GmbH, Mannheim, 
Germany 
NaCl (≥ 99%, Ph.Eur.) 
 
 
Carl Roth GmbH, Germany 
NaOH (0.1 mol/L) Carl Roth GmbH, Germany 
NaH2PO4 (≥ 99%, Ph.Eur.) 
 
Carl Roth GmbH, Germany 
Na2HPO4 (≥ 98%, Ph.Eur.) 
 
 
Sigma-Aldrich Chemie GmbH, 
Germany 
Na3PO4  (≥ 98%,ACS) 
 
 
Sigma-Aldrich Chemie GmbH, 
Germany 
(NH4)2SO4  (≥ 99.5%, ACS) 
 
 
Carl Roth GmbH, Germany 
10 x PBS Roche Diagnostics GmbH, Mannheim, 
Germany 
Pharmalyte 3-10 Proteinsimple, USA 
pI markers 7.05 & 9.77 (iCE) Proteinsimple, USA 
Streptavidin-sepharose GE Healthcare, United Kingdom 
TRIS (≥ 99%, Ph.Eur.) 
 
 
Carl Roth GmbH, Germany 
Tween 20 Roche Diagnostics GmbH, Mannheim, 
Germany 
Urea (≥ 99.5%, Ph.Eur.) 
 
Sigma-Aldrich Chemie GmbH, 
Germany 
2.2. Kits 
The following kits were used in this work: 
 
 
Instruments and chromatography columns 
23 
 
Table 2-2: Kits 
 
Description Provider 
Amine Coupling Kit (BiaCore) GE Healthcare, United Kingdom 
Bulk BirA Avidity Biotechnologies, USA 
FabRICATOR® Genovis, Sweden 
His Capture Kit GE Healthcare, United Kingdom 
Protein Series II Kit (Bioanalyzer) Agilent Technologies, USA 
2.3. Instruments and chromatography columns  
The following instruments and chromatography columns were used: 
Table 2-3: Instruments and chromatography columns 
 
Description Provider 
Instruments  
Analytical balance (XS105 dual range) Mettler Toledo, Switzerland 
Anesthesia station Fortec Medic Supplies Ltd, Kenya 
Autosampler (iCE) Prince Technologies, Netherlands 
Biacore T100 GE Healthcare, United Kingdom 
Bioanalyzer (2100) Agilent technologies, USA 
Electrical pipettes (50-1,200 µL) Eppendorf, Germany 
Filter (0.22 & 0.45 µm) Pall Corporation, USA 
Freezer (Liebherr premium, -20°C) Liebherr, Switzerland 
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Freezer (6485, -50- -85 °C) GFL, Germany 
HydroFlex™ (Microplate washer) Tecan Group, Switzerland 
iCE 280 system Proteinsimple, USA 
NanoDrop™1000 (Spectrophotometer) Thermo Fisher Scientific, Germany 
Pipettes (2.5-1,000 µL) Eppendorf, Germany 
Refrigerator (Liebherr comfort) Liebherr, Switzerland 
SevenEasy™ (pH-Meter) Mettler Toledo, Switzerland 
Sunrise™ (Photometer) Tecan Group, Switzerland 
Super-Q water systems Millipore, Germany 
Thermomixer comfort®  Eppendorf, Germany 
Termoshaker (Grant bio PHMP-4) Keison Products, United Kingdom 
Uvikon® XL (UV VIS Photometer) GOEBEL Instrumentelle Analytik 
GmbH, Germany 
Vortex-Genie 2 Scientific industries, USA 
Chromatography columns  
FcRn affinity chromatography column 
(production see 3.4.2.2) 
Roche Diagnostics GmbH, Mannheim, 
Germany (internal use only) 
TSKgel Ether-5PW (10 µm, 
7,5 mmx7,5 cm, HIC column)  
Tosoh Corporation, Japan 
Antibodies and proteins 
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Waters Biosuite™ 250 (7.8 x 300 mm, 
SEC column) 
Waters Corporation, USA 
2.4. Antibodies and proteins 
Antibodies, receptors and cytokines used are listed in Table 2-4. Antibodies used as 
model antibodies and for the ELISA-measurements were produced only for internal 
use and are not commercially available. 
Table 2-4: Antibodies and proteins 
 
Description Provider 
Model system antibodies  
Briakinumab (sequence origin: 
PN WO2001014162-A2) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Ustekinumab (sequence origin:      
CAS Registry Number 815610-63-0) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 1 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 2 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 3 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 4 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 5 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 6 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 7 Roche Diagnostics GmbH, Mannheim, 
Germany 
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mAb 8 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 9 Roche Diagnostics GmbH, Mannheim, 
Germany 
mAb 10 Roche Diagnostics GmbH, Mannheim, 
Germany 
Bevacizumab (sequence origin: 
DB00112) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Bevacizumab-variant Roche Diagnostics GmbH, Mannheim, 
Germany 
Antibodies for ELISA measurements  
<huFc>-Dig Roche Diagnostics GmbH, Mannheim, 
Germany 
<Dig>-POD Roche Diagnostics GmbH, Mannheim, 
Germany 
<muFc>-POD Roche Diagnostics GmbH, Mannheim, 
Germany 
<huFc>-Fab’-Bi Roche Diagnostics GmbH, Mannheim, 
Germany 
Calibration standard (conjugate of 
huIgG and muIgG) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Antibody for SPR measurements  
<huFcPan> Roche Diagnostics GmbH, Mannheim, 
Germany (internal use only) 
Proteins  
muFcɣRI R&D systems GmbH, USA 
Mice 
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huFcRn Roche Diagnostics GmbH, Mannheim, 
Germany 
huIL-12 Cell sciences, USA 
huIL-23 R&D systems GmbH, USA 
muIL-12 R&D systems GmbH, USA 
muIL-23 R&D systems GmbH, USA 
2.5. Mice 
Animal studies were approved by the Government of Upper Bavaria, Germany 
(permit number 55.2-1-54-2532.2-28-10) and performed in an AAALAC accredited 
animal facility according to the European Union Normative for Care and Use of 
Experimental Animals. Mouse husbandry was carried out under specific pathogen 
free conditions and the animals were housed in standard cages having free access to 
food and water during the whole study period. The two following mice strains were 
used in this work: 
Table 2-5: Mice 
 
Description Provider 
B6.Cg-<tm1Dcr>Tg(FCGRT)276Dcr 
(human FcRn transgenic mice) 
Jackson Laboratory, USA 
B6.129X1-Fcgrt<tm1Dcr>/DcrJ     
(FcRn knockout mice) 
Jackson Laboratory, USA 
2.6. Buffer compounds 
The following buffer compounds were used in this work. All buffers were prepared 
using demineralized, sterile water and the pH was adjusted using hydrochloric acid 
and sodium hydroxide. 
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Table 2-6: Buffer compounds 
 
FcRn column buffers, pH gradient 
Eluent A, pH 5.5   
MES 20 mM 
NaCl 140 mM 
Eluent B, pH 8.8  
TRIS 20 mM 
NaCl 140 mM 
FcRn column buffers, salt gradient 
Eluent A, pH 7.8  
MES 10 mM 
Eluent B, pH 7.8  
MES 10 mM 
NaCl 250 mM 
FcRn column preparation buffers, pH 7.5 
NaH2PO4 20 mM 
NaCl 150 mM 
Formulation buffer, pH 6.0 
Histidine 20 mM 
NaCl 140 mM 
HIC buffers, pH 7.0 
Eluent A, pH 7.0  
(NH4)2SO4 1.5 M 
Na3PO4 
 
25 mM 
Software 
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Eluent B, pH 7.0  
Na3PO4 
 
25 mM 
1 x PBS, pH 6.0/ pH 7.4 
KH2PO4 1 mM 
Na2HPO4 10 mM 
NaCl 137 mM 
KCl 2.7 mM 
SEC buffer, pH 7.0 
KH2PO4 200 mM 
KCl 250 mM 
Wash buffer ELISA, pH 7.4 
KH2PO4 1 mM 
Na2HPO4 10 mM 
NaCl 137 mM 
KCl 2.7 mM 
Tween 20 0.05 % 
Universal buffer for ELISA 
Produced by Roche Diagnostics, Mannheim, Germany (internal use only, 
compounds not published). 
2.7. Software 
The software systems used are listed in Table 2-7. 
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Table 2-7: Software 
 
Description Provider 
Biacore T100 control/ evaluation GE Healthcare, United Kingdom 
Chromeleon Dionex, Germany 
DiscoveryStudio Pro, Version 3.5 Accelrys Inc., USA 
European Molecular Biology Open 
Software Suite (EMBOSS) 
European Bioinformatics Institute 
(EBI), United Kingdom 
 
 
General Protein Mass Analysis for 
Windows (GPMAW) 9.10 
ChemSW, USA 
Microsoft office 2010 Microsoft, USA 
WinNonlin 5.3 Pharsight, USA 
XLfit4 IDBS, United Kingdom 
2.8. Consumable supplies  
The following table gives information about the consumable supplies used. 
Table 2-8: Consumable supplies 
 
Description Provider 
BiaCore CM5 sensor chip GE Healthcare, United Kingdom 
26-gauge injection needle B.Braun Melsungen AG, Germany 
Hematocrit capillary Hirschmann, Inc., USA 
Microvette 500Z-Gel serum tubes Nümbrecht, Germany 
Streptavidin MTP (high capacity) Roche Diagnostics GmbH, Mannheim, 
Germany 
Preincubation MTP Thermo Scientific, USA 
1 mL syringe Dispomed Witt oHG, Germany 
1 ml XK column GE Healthcare, United Kingdom 
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3. Methods 
The method section is divided in 6 parts. In the first part, the production of the 
antibodies used in this work is described. Afterwards, in part 2 and 3, the antibodies 
were biochemically and functionally characterized to test the correct production and 
to check for reasons that could explain differences in PK. Part 4 deals with the 
analysis of the FcRn-mAb interaction to elucidate if PK differences are due to 
different FcRn interactions. The influence of different FcRn-mAb interactions on in 
vivo PK is investigated in part 5. Finally, the transferability of the previous results to 
another independent mAb model system is tested and is described in part 6.  
3.1. Production 
The antibodies used in this work were Briakinumab (ABT 874, J 695, Ozespa®, 
SEQ ID NO 36, PN WO2001014162-A2), Ustekinumab (CNTO 1275, Stelara®, 
CAS Registry Number 815610-63-0) as well as ten variants of Briakinumab and 
Ustekinumab, hereafter referred to as mAb 1 to mAb 10, respectively. In total, 
twelve IgGs were investigated. 
All antibodies were kindly provided by the department of LMR Discovery (Roche 
Diagnostics GmbH, Mannheim, Germany, Site Penzberg). Briefly, synthetic genes 
were produced for Briakinumab, Ustekinumab, mAb 5 and mAb 6 at Geneart (Life 
technologies GmbH, USA). Site-directed mutagenesis was used to mutate specific 
amino acids to produce mAb 1, mAb 2, mAb 7, mAb 8, mAb 9 and mAb 10. MAb 3 
was transfected with plasmids encoding Ustekinumab heavy chains and Briakinumab 
light chains and mAb 4 vice versa. All monoclonal antibodies used in the 
experiments were transiently expressed in HEK293 cells and purified using 
protein A chromatography and size exclusion chromatography (SEC) at the 
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department of Biochemical & Analyticals Research (Roche Diagnostics GmbH, 
Mannheim, Germany, Site Penzberg). Antibodies were formulated in buffer 
containing 20 mM histidine, 140 mM sodium chloride (NaCl), pH 6.0, and stored 
frozen at -80°C until analysis. 
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3.2. Biochemical characterization 
The biochemical characterization of the mAbs included the analysis of protein 
concentration, size and molecular weight. Furthermore, hydrophobicity and charge 
distribution were analyzed and compared.  
3.2.1. Determination of mAb concentration 
Protein concentration was determined by photometric measurement of the 
absorbance at 280 nm and 320 nm after buffer blank subtraction. The absorbance at 
320 nm was subtracted from the absorbance at 280 nm to correct light scattering and 
turbidity and this value was used to calculate the protein concentration according to 
the law of Lambert-Beer. The concentration was determined as average of three 
measurements. The absorbance spectrum is shown exemplarily for one antibody in 
Figure 3-1. 
 
Figure 3-1: Photometric absorbance 
Absorbance spectrum of an IgG1 antibody.  
3.2.2. Determination of mAb molecular weight 
The Agilent 2100 Bioanalyzer was used for analysis of the antibody molecular 
weight. In principle, the analysis is based on capillary electrophoresis on a chip 
system (CE-SDS), which provides sizing and quantitation information of the 
proteins. Samples were reduced into HCs and LCs using dithiothreitol (DTT). 
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Afterwards reduced and non-reduced samples were incubated with sodium dodecyl 
sulfate (SDS)-containing sample buffer at 90°C (Thermomixer comfort®, 
Eppendorf, Germany) for 5 min, centrifuged and loaded on the chip. Fluorescence 
dye molecules intercalated with protein-SDS micelles and the complexes were 
detected by laser-induced fluorescence. Data was translated into gel-like images 
(bands, Figure 3-2) and electropherograms (peaks). The size of each fragment in the 
sample was calculated with the use of a ladder containing proteins of known sizes. 
Integration of the electropherograms showed the percentage of fractions having the 
same molecular weight referred to total area of all fractions. 
 
Figure 3-2: Purity and molecular weight  
Gel-like images of an intact IgG1 antibody and of HCs and LCs after DTT-reduction. 
3.2.3. Determination of mAb size 
SEC analysis was used for determination of the antibody size or more accurately of 
the apparent hydrodynamic radius. SEC was conducted using a Waters Biosuite™ 
250 column on a Summit HPLC-system. The elution peaks were monitored by UV 
absorption at 280 nm. Isocratic chromatography was conducted at room temperature 
(RT) using an aqueous buffer composed of 200 mM potassium dihydrogen phosphate 
and 250 mM potassium chloride at pH 7.0 and a flow-rate of 0.5 mL/min. Each 
sample contained 25 µg mAb per injection. The chromatograms were integrated 
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using the Chromeleon software. This is shown exemplarily in Figure 3-3. The 
fraction of higher molecular weight species (HMWs) includes dimers and larger 
soluble oligomers. It was determined as relative area of the respective peaks referred 
to the total area of all peaks including HMW peaks, the monomer peak and the peaks 
of the lower molecular weight species (LMWs).  
 
Figure 3-3: SEC chromatogram with included integration borders 
HMWs including oligomers and dimers elute first, followed by monomer and LMWs. 
3.2.4. Determination of mAb hydrophobicity 
The apparent hydrophobicity of the antibodies was measured using hydrophobic 
interaction chromatography (HIC). HIC analysis was conducted using a TSKgel-
5PW column on a Summit HPLC-system. The elution peaks were monitored by UV 
absorption at 280 nm. Decreasing salt-gradient chromatography was conducted at RT 
starting with aqueous buffer composed of 1.5 M ammonium sulfate, 25 mM sodium 
phosphate, pH 7.0, to 0 mM ammonium sulfate, 25 mM sodium phosphate, pH 7.0, 
and a flow-rate of 0.8 mL/min. Each sample contained 30 µg mAb per injection. The 
chromatograms were integrated using the Chromeleon software. Low and high 
hydrophobic reference samples (RS) were used to classify the antibodies according 
to their hydrophobic profile. 
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Figure 3-4: HIC chromatogram with reference samples 
Low hydrophobic samples elute earlier than higher hydrophobic ones. The hydrophobicity of 
the sample is classified with the help of low and high hydrophobic reference samples. 
3.2.5. Analysis of stressed mAbs 
Stress-tests were used to analyze the protein stability and the tendency for 
aggregation of Briakinumab and Ustekinumab.  
First, samples were tested for their response to freeze-thaw stress. Six freeze-thaw 
cycles were performed using 1 mL of the samples formulated in 20 mM histidine, 
140 mM NaCl, pH 6.0. One cycle consisted of storage at -80°C and RT for 2 h until 
the samples were completely frozen and thawed, respectively. Afterwards the 
samples were analyzed for protein concentration and MW distribution according to 
the methods described above. 
Second, the storage stability and the response to accelerated temperature stress was 
tested. Samples were diluted in 20 mM histidine, 140 mM NaCl, pH 6.0, and in PBS, 
pH 7.4, to a concentration of 1 mg/mL. Afterwards samples were stored at -80°C and 
37°C, respectively, for 7 days. Then the samples were analyzed for protein 
concentration and MW distribution according to the methods described above. 
3.2.6. Determination of mAb isoelectric point 
The isoelectric point (pI) of the antibodies was determined using capillary isoelectric 
focusing (cIEF) with an iCE280 system connected to an autosampler. The separation 
cartridge in the iCE280 unit contained a fluorocarbon-coated fused-silica capillary 
with an internal diameter of 100 μm and a separation length of 5 cm. As anolyte and 
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catholyte, 80 mM phosphoric acid containing 0.1% w/w methyl cellulose and 
100 mM sodium hydroxide containing 0.1% w/w methyl cellulose were used, 
respectively. Methyl cellulose was used to increase the viscosity of the matrix and 
thus the resolution. Samples were rebuffered in 10 mM histidine buffer and 40 μL of 
the samples (c = 1.2 mg/mL) were added to 160 μL of a mixture containing 3% v/v 
carrier Pharmalyte 3-10, 0.2% v/v pI markers 7.05 and 9.77, 0.35% w/w methyl 
cellulose and 30 % w/w urea. The pI markers were used to calibrate the pH gradient 
formed by the pharmalyte in the capillary. IEF was carried out for 30 sec at 500 volt 
followed by 6 min at 3000 volt. The chromatograms were integrated using the 
Chromeleon software. This is shown exemplarily in Figure 3-5.  
 
Figure 3-5: iCE chromatogram with pI markers 
Upper and lower pI markers were used to calibrate the pH gradient.  
The theoretical isoelectric points were also calculated by the protein sequence using 
GPMAW (Version 9.10) and standard settings (Skoog and Wichman 1986). As 
plausibility check, calculated and measured pIs were compared. 
In addition to the isoelectric points, the pH dependent net charge of the VH, VL and 
Fv domain of Briakinumab and Ustekinumab at pH 6.0 and pH 7.4 were calculated 
with the open-source program EMBOSS iep assuming all cysteines are involved in 
disulfide bridges. 
3.2.7. Charge distribution analysis 
The 3D-charge distribution in the Fv domain was calculated for all mAbs. 
Furthermore FcRn was studied for the presence of positively or negatively charged 
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regions. Generation of homology models and calculation of isopotential surfaces 
were kindly performed by Dr. Hubert Kettenberger (Biochemical & Analyticals 
Research, Roche Diagnostics GmbH, Mannheim, Germany, Site Penzberg). 
Briefly, a homology model for the Briakinumab Fab fragment was generated using 
modeller 9v7 and PDB structure 1AQK (Faber et al. 1998) as a template. The 
isopotential surfaces for Briakinumab and Ustekinumab Fab fragments were 
calculated from this model (Briakinumab) or the crystal structure of Ustekinumab 
(PDB ID 3HMX), respectively. Structures were protonated using the “prepare 
protein” protocol with CHARMm force field in DiscoveryStudio Pro, Version 3.5 
(Accelrys Inc., USA) at pH 7.4 and an ionic strength of 145 mM. 
For the variants of Briakinumab and Ustekinumab, homology models of the Fab 
fragments were generated. For the Briakinumab variants, mAb 1, mAb 4, mAb 5 and 
mAb 7-10, the Fab fragment homology model was generated using the Briakinumab 
model described above. The Fab fragment homology model for the Ustekinumab 
variants, mAb 2, mAb 3 and mAb 6, was generated using the crystal structure of 
Ustekinumab (PDB ID 3HMX). The isopotential surfaces of the Fab fragments were 
calculated based on these models as described above. 
The isopotential surface of FcRn was calculated using the published crystal structure 
of human FcRn (PDB 4N0U (Oganesyan et al. 2014)) as described above.  
3.2.8. IdeS cleavage  
Briakinumab and Ustekinumab were cleaved using the FabRICATOR® Kit 
(Genovis, Sweden). The enzyme FabRICATOR® consists of recombinant 
immunoglobulin-degrading enzyme from Streptococcus pyogenes (IdeS). IdeS is a 
proteolytic enzyme that cleaves IgG only at one specific site in the lower hinge 
region, resulting in F(ab’)2 fragment and Fc monomers (Figure 3-6) (Johansson et al. 
2008). Antibodies were diluted in cleavage buffer consisting of 50 mM Na3PO4, 
150 mM NaCl, pH 6.6, to a concentration of 1 mg/mL. To each µg antibody 1 unit 
FabRICATOR® was added and the solution was incubated for 30 min at 37°C. 
Afterwards the cleaved antibodies were tested using CE-SDS and analytical SEC. 
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Figure 3-6: Antibody cleavage using IdeS 
Antibody cleavage site is in the lower hinge region generating F(ab’)2 fragment and Fc 
monomers. 
3.2.9. Complex of mAb and IL-12 
Briakinumab and Ustekinumab were bound to their target IL-12 by mixing 0.3 nmol 
mAb with 0.2 nmol IL-12. In addition, a Briakinumab-IL-12 complex was assembled 
using an IL-12 excess by mixing 0.3 nmol mAb with 0.8 nmol IL-12. The mAb-IL12 
complexes were incubated for 30 min at RT. Afterwards the mAb-IL-12 complex 
was analyzed for FcRn interaction (3.4.2.2).  
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3.3. Functional characterization 
The functional characterization consisted of analysis of the interaction with human 
IL-12 and IL-12/-23 of different species. Furthermore the interaction with an mouse 
Fcɣ receptor (muFcɣR) was analyzed by comparison of binding levels to the mouse 
Fcɣ receptor I (muFcɣRI), which is the FcɣR having the highest affinity to IgG1 
(Nimmerjahn and Ravetch 2008).  
3.3.1. Interaction with human IL-12 
The interaction with human IL-12 was analyzed using a target-specific enzyme-
linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). 
3.3.1.1. ELISA 
For the specific ELISA, biotinylated human IL-12 was used as capture reagent. 
Recombinant human IL-12 (Cell sciences, USA) was reconstituted and biotinylated 
using the Bulk BirA biotinylation kit according to the manufacturer’s instructions 
(Bulk BirA, Avidity Biotechnologies, USA). Biotin-protein ligase, birA enzyme, 
activates biotin to form biotinyl 5´ adenylate and transfers the biotin to biotin-
accepting proteins. To couple IL-12 with biotin, 1 mg IL-12 were mixed with 83 µL 
of the following mixture: 2.5 mL PBS and 1 tablet complete protease inhibitor 
(cOmplete ULTRA tablets, Roche Diagnostics GmbH, Mannheim, Germany), 
750 µL Biomix A, 750 µL Biomix B and 5 µL BirA. The mixture was incubated 
overnight at RT. The biotinylated IL-12 was dialyzed against 50 mM potassium 
phosphate buffer, pH 7.4. After filtration using a 0.22 µm filter, the concentration 
was measured by UV/Vis spectroscopy (NanoPhotometer, Implen Inc., USA). The 
biotinylated human IL-12 was stored frozen at -80°C until use. 
For quantitative determination of the antibodies bound to human IL-12, a specific 
ELISA was used. The ELISA design is shown in Figure 3-7. 
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Figure 3-7: Principle of the specific ELISA 
Streptavidin-coated MTPs were coated with biotinylated capture reagent (IL-12-Bi). 
Afterwards antibodies were added at various dilutions. Bound mAbs were detected by 
subsequent incubation with digoxigenin-labeled detection antibody (<huFc>-Dig), followed 
by incubation with anti-digoxigenin Fab fragments conjugated to horseradish peroxidase 
(<Dig>-POD). ABTS was used as HRP substrate to form a colored reaction product. 
Absorbance of the resulting reaction product was read at 405 nm with a reference 
wavelength at 490 nm. 
Preparation: All reagents and buffers were raised to RT before usage. Dilutions were 
made in assay buffer (Universal buffer for ELISA). Incubation steps were performed 
under agitation at 500 rpm at RT and were followed by 3 washing steps using 300 µL 
wash buffer (PBS, 0.05% Tween20) per well. 
Capture reagent: A streptavidin-coated microtiter plate (MTP) was coated with 
100 µL/well biotinylated IL-12-solution (IL-12-Bi, concentration 100 ng/mL) and 
incubated for 60 min.  
Samples: Antibody stock solutions were serially 1:2 diluted starting at 12 ng/mL. 
The resulting concentrations were 12, 6, 3, 1.5, 0.75, 0.38, 0.19 and 0 ng/mL. 100 µL 
of each antibody dilution as well as positive and negative control samples were 
added to each well and incubated for 60 min. All samples were analyzed in 
duplicates. 
First detection reagent: A volume of 100 µL of digoxigenin-labeled antibody 
(50 ng/mL <huFc>-Dig) which binds to the Fc region of human IgGs was added to 
each well and incubated for 60 min. 
Second detection reagent: 100 µL of anti-digoxigenin Fab fragments conjugated to 
horseradish peroxidase (15 mU/mL <Dig>-POD) were added to each well and 
incubated for 60 min. 
Substrate reaction: A volume of 100 µL substrate solution 2,2'-azino-bis(3-
Methods 
42 
 
ethylbenzothiazoline-6-sulphonic acid) (ABTS) was added to the MTP per well and 
the extinction was measured at 405 nm with a reference wavelength of 490 nm. At an 
optical density (OD) of 2.0 the measurement was stopped.  
Calculation: Using a 4-parameter fit (Wiemer-Rodbard equation    
 
        
 ) of 
the “XLfit4” software, the absorbance-concentration curves were calculated and 
compared to each other. Furthermore the concentration of each mAb was calculated 
using the fit of the Briakinumab calibration curve to obtain IL-12 binding relative to 
Briakinumab (Briakinumab = 100%).  
Acceptance criteria: The standard calibration curve must consist of at least 5 values. 
The absorbance of the lowest calibration standard should be below 0.1 OD. For 
sample analysis at least two dilutions of the sample should be within the linear range 
of the standard calibration curve.  
Accuracy: The accuracy of the ELISA was determined to be ± 20% according to 
Roche internal guidelines.  
3.3.1.2. SPR 
Affinity of the mAbs to recombinant human IL-12 was analyzed by SPR with a 
BiaCore T100 instrument. The assay was performed using PBS including 
0.05% Tween20, pH 7.4, as running and dilution buffer. An <huFcPan>-capture 
antibody recognizing the mAb’s Fc region in 10 mM sodium acetate buffer, pH 4.5, 
was immobilized onto a CM5 chip to a level of 12,400 response units (RU). This 
capture antibody bound the mAbs at their Fc region to a level of about 50 RU using a 
flow rate of 10 µL/min for 30 sec. Afterwards different dilutions of human IL-12 
were prepared: 0.25, 0.75, 2.2, 6.7, 20, 60, 180 nM and each sample was injected at a 
flow rate of 30 µL/min. Association and dissociation times of 120 and 600 sec were 
used, respectively. The chip was regenerated by injection of 100 mM phosphoric 
acid for 60 sec, followed by injection of 5 mM sodium hydroxide solution at a flow 
rate of 10 µL/min. The equilibrium dissociation constant (KD) was calculated using 
steady state affinity calculation at the BiaCore T100 evaluation software.  
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3.3.2. Interaction with IL-12 and IL-23 of different species 
The interaction of the mAbs used in the in vivo study (Briakinumab, Ustekinumab, 
mAb 8 and mAb 9) with recombinant human IL-12, human IL-23, mouse IL-12 and 
mouse IL-23 was analyzed using a BiaCore T100 instrument. The assay was 
performed using PBS including 0.05% Tween20, pH 7.4 as running and dilution 
buffer. An <huFcPan>-capture antibody in 10 mM sodium acetate buffer, pH 4.5, 
was immobilized onto a CM5 chip to a level of 12,400 RU. This capture antibody 
bound the mAbs at their Fc region to a level of about 50 RU using a flow rate of 
10 µL/min for 30 sec. Afterwards 130 nM of human IL-12, human IL-23, mouse IL-
12 and mouse IL-23 were injected at a flow rate of 30 µL/min. Association and 
dissociation times of 120 and 600 sec were used, respectively. The chip was 
regenerated by injection of 100 mM phosphoric acid for 60 sec, followed by 
injection of 5 mM sodium hydroxide solution at a flow rate of 10 µL/min. The 
binding levels of each antibody to each Interleukin were determined using 
BiaCore T100 evaluation software and compared to each other.  
3.3.3. Interaction with mouse FcɣRI 
Binding levels of the mAbs used in the in vivo study (Briakinumab, Ustekinumab, 
mAb 8 and mAb 9) to the mouse Fcɣ receptor I (muFcɣRI) were analyzed using a 
BiaCore T100 instrument. The assay was performed using HBS P+, pH 7.4 as 
running and dilution buffer. An <His>-capture antibody in 10 mM sodium acetate 
buffer, pH 4.5, was immobilized onto a CM5 chip to a level of 12,500 RU (His 
Capture Kit, GE Healthcare, United Kingdom). This capture antibody bound 
muFcɣRI to a level of about 410 RU using a flow rate of 30 µL/min for 60 sec. 
Afterwards 25 nM of the mAbs were injected at a flow rate of 30 µL/min. 
Association and dissociation times of 60 and 180 sec were used, respectively. The 
chip was regenerated by injection of 10 mM glycine-HCl, pH 1.5, at a flow rate of 
30 µL/min for 60 sec. The binding levels of each antibody to muFcɣRI were 
determined using BiaCore T100 evaluation software and compared to each other.  
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3.4. FcRn-mAb interaction 
The FcRn-mAb interaction consists of two phases that are important to be analyzed: 
FcRn-mAb binding at pH 6.0 and FcRn-mAb dissociation at higher pHs. Therefore, 
the FcRn-mAb interaction was first studied by analyzing the FcRn-IgG affinity at 
pH 6.0 and afterwards by analyzing the FcRn-mAb dissociation at elevated pHs. 
3.4.1. FcRn-mAb affinity at pH 6.0 
The steady state binding levels and the KDs for huFcRn and the mAbs were 
determined at pH 6.0 using a BiaCore T100 instrument. Human FcRn in 
10 mM sodium acetate buffer, pH 4.5, was immobilized on a BiaCore CM5-
biosensor chip via amine-coupling to a level of 50 RU. The assay was performed 
using PBS containing 0.05% Tween20 adjusted to pH 6.0 as running and dilution 
buffer. Different dilutions of the mAbs were prepared: 23, 47, 94, 188, 375, 750, 
1500 nM and each sample was injected at a flow rate of 5 µL/min. Association and 
dissociation times of 600 and 360 sec were used, respectively. The chip was 
regenerated by injection of PBS containing 0.05% Tween20 at pH 7.5. The KD was 
calculated as steady state affinity using BiaCore T100 evaluation software and 
normalized to the KD of Ustekinumab. The measurements were performed in 
triplicate and the mean and standard deviation was determined.  
3.4.2. FcRn-mAb dissociation 
The dissociation of FcRn and the mAbs was analyzed using SPR and FcRn affinity 
chromatography. 
3.4.2.1. FcRn-mAb dissociation using SPR 
The steady state binding levels and the KDs for huFcRn and the mAbs were 
determined at different pH-values to evaluate the pH dependency of the FcRn 
affinity. The experimental setup is the same as in 3.4.1, except that the running 
buffers used were PBS containing 0.05% Tween20 adjusted to pH 6.4, pH 6.6, 
pH 6.8, pH 7.0 and pH 7.2, respectively.  
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3.4.2.2. FcRn-mAb dissociation using FcRn affinity chromatography 
FcRn was biotinylated using the Bulk BirA biotinylation kit according to the 
manufacturer’s instructions (Bulk BirA, Avidity Biotechnologies, USA). To couple 
FcRn with biotin, 3 mg FcRn were mixed with 250 µL of the following mixture: 
2.5 mL PBS and 1 tablet complete protease inhibitor (cOmplete ULTRA tablets, 
Roche Diagnostics GmbH, Mannheim, Germany), 750 µL Biomix A, 750 µL 
Biomix B and 5 µL BirA. The mixture was incubated overnight at RT. The 
biotinylated FcRn was dialyzed against 20 mM sodium dihydrogen phosphate buffer 
comprising 150 mM NaCl, pH 7.5 at 4°C overnight to remove uncoupled biotin. For 
coupling to streptavidin sepharose, 1 g streptavidin-sepharose was added to the 
biotinylated and dialysed FcRn and incubated at 4°C overnight. The FcRn-
derivatized sepharose was packed in a 1 mL XK column and the FcRn column was 
then equilibrated with 20 mM 2-(N-morpholine)-ethanesulfonic acid (MES) sodium 
salt buffer containing 140 mM NaCl, pH 5.5. 
3.4.2.3. FcRn affinity chromatography using a pH gradient 
The pH gradient FcRn affinity chromatography was conducted using the prepared 
FcRn-column on a Summit HPLC-system. The elution peaks were monitored at 
280 nm. Each sample contained 30 µg mAb per injection and was prepared in 
20 mM MES sodium salt, 140 mM NaCl, pH 5.5. Antibodies were eluted by a linear 
pH gradient ranging from pH 5.5 to 8.8 within 120 min using 20 mM MES sodium 
salt, 140 mM NaCl, pH 5.5, and 20 mM TRIS, 140 mM NaCl, pH 8.8, as eluents and 
a flow rate of 0.5 mL/min. FcRn column chromatography shows binding at acidic pH 
(pH 5.5– 6.0) and release at higher pH values. For complete elution of the antibodies, 
the pH was increased in the gradient up to pH 8.8. The chromatograms were 
integrated using the Chromeleon software. The experiments were performed at RT. 
The elution profile was obtained by continuous measurement of the absorbance at 
280 nm. The time taken for an analyte peak to reach the detector after sample 
injection was called the retention time. The FcRn affinity chromatograms of all 
mAbs were intensity-normalized for clarity. To determine the elution pH at particular 
retention times, samples were collected every 5 min and the pH was measured 
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offline. The nearly linear range was fitted using a 4-parameter fit (fit        
          ) of the “XLfit4” software. (Figure 3-8). The retention times 
were measured and the elution pHs were calculated on the basis of the 4-parameter 
fit. 
 
Figure 3-8: FcRn column elution pH plotted against the retention time 
Samples were collected every 5 min and the pH was measured offline. Data was fitted using 
a 4-parameter fit (fit y=A*x
3
+B*x
2
+C*x+D). 
3.4.2.4. FcRn affinity chromatography under high ionic strength conditions 
Higher ionic strength conditions were used to analyze charge-mediated effects on 
FcRn-mAb interaction. Therefore, the FcRn affinity chromatography was conducted 
as described above, but using buffers supplemented with different NaCl 
concentrations. Buffers were used containing 20 mM MES sodium salt, pH 5.5, and 
20 mM TRIS, pH 8.8, each comprising 140 mM, 170 mM, 200 mM, 250 mM, 
300 mM or 400 mM NaCl. 
3.4.2.5. FcRn affinity chromatography using a salt gradient 
The salt gradient FcRn affinity chromatography analyzes charge-mediated FcRn-IgG 
interactions at constant pH. The salt gradient FcRn affinity chromatography was 
conducted using the prepared FcRn-column on a Summit HPLC-system. The 
samples were prepared in 10 mM MES sodium salt, pH 7.8. Each sample contained 
30 µg mAb per injection. Antibodies were eluted by a linear salt gradient from 0 nM 
to 250 mM NaCl within 60 min using 10 mM MES sodium salt, pH 7.8, and 10 mM 
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MES sodium salt, 250 mM NaCl, pH 7.8, as eluents and a flow rate of 0.5 mL/min. 
The chromatograms were integrated using the Chromeleon software. The elution 
profile was obtained by continuous measurement of the absorbance at 280 nm. 
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3.5. In vivo PK study 
To analyze if different FcRn-mAb interactions have an influence on PK, in vivo 
studies in human FcRn transgenic and FcRn knockout mice were performed. The PK 
studies were conducted in human FcRn transgenic mice with Briakinumab, 
Ustekinumab, mAb 8 and mAb 9 and in FcRn knockout mice with Briakinumab, 
Ustekinumab and mAb 9. All animal experiments were kindly performed by the 
department of LMR Discovery (Roche Diagnostics GmbH, Mannheim, Germany, 
Site Penzberg). The studies were approved by the Government of Upper Bavaria, 
Germany (permit number 55.2-1-54-2532.2-28-10) and performed in an AAALAC 
accredited animal facility according to the European Union Normative for Care and 
Use of Experimental Animals. Mouse husbandry was carried out under specific 
pathogen free conditions and the animals were housed in standard cages having free 
access to food and water during the whole study period. 
3.5.1. Mice 
B6.Cg-Fcgrt<tm1Dcr>Tg(FCGRT)276Dcr mice deficient in mouse FcRn α-chain 
gene, but hemizygous transgenic for a human FcRn α-chain gene (muFcRn-/-huFcRn 
tg +/-, line 276) were used for the PK studies. Mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA) (female, age 4-10 weeks, weight 17-22 g at time 
of dosing). 
B6.129X1-Fcgrt<tm1Dcr>/DcrJ mice are homozygous FcRn α-chain knockout mice 
(muFcRn -/-). These mice cannot express mouse FcRn. A detailed description of the 
mouse strain is provided by Roopenian et al. (2003) and Roopenian et al. (2010). 
Mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) (female, 
age 4-10 weeks, weight 15-21 g at time of dosing). 
3.5.2. Study design 
Treatment: A single dose of antibody was injected i.v. via the lateral tail vein at a 
dose level of 10 mg/kg and a dose volume of 10 mL/kg.  
Blood sampling: Blood was collected via the retro bulbar venous plexus from each 
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animal for the determination of the compound levels. Each mouse was subjected 
twice to retro-orbital bleeding, performed under light anesthesia with Isoflurane™; a 
third blood sample was collected at the time of euthanasia. Blood was collected into 
serum tubes using hematocrit capillaries. After 2 h incubation at RT, samples were 
centrifuged for 3 min at 9.300 g at 4°C to obtain serum. After centrifugation, serum 
samples were stored frozen at -80°C until analysis. Blood sampling was performed 
according to a schedule to ensure that the weekly collected blood volume did not 
exceed 7.5% of the mice blood volume (Diehl et al. 2001). Furthermore blood can 
only be collected via the retro bulbar venous plexus triply per mouse, once from the 
right eye, once from the left eye and a third time at the time of euthanasia (Hack et 
al. 2013). Because of these animal welfare guidelines it was not possible to collect 
blood from each mouse at each of the 9 time points to achieve single-animal kinetics. 
Therefore the mice were divided into 3 groups of 6 mice each to cover 9 serum 
collection time points in total (Table 3-1 and Table 3-2) 
Table 3-1: Blood sampling schedule- human FcRn transgenic mice 
Mice were divided in 3 groups with 6 mice each to cover 9 blood sampling time points 
indicated as (X) over a study period of 4 weeks. 
Time 
after 
treatment 
(h) / (d) 
Group 1 Group 2 Group 3 
M
1 
M
2 
M
3 
M
4 
M
5 
M
6 
M
1 
M
2 
M
3 
M
4 
M
5 
M
6 
M
1 
M
2 
M
3 
M
4 
M
5 
M
6 
0.08 / 0 X X X X X X             
2 / 0       X X X X X X       
8 / 0             X X X X X X 
24 / 1 X X X X X X             
48 / 2       X X X X X X       
168 / 7             X X X X X X 
336 / 14 X X X X X X             
504 / 21       X X X X X X       
672 / 28             X X X X X X 
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Table 3-2: Blood sampling schedule- FcRn knockout mice 
Mice were divided in 3 groups with 6 mice each to cover 9 blood sampling time points 
indicated as (X) over a study period of 2 weeks. 
Time 
after 
treatment 
(h) / (d) 
Group 1 Group 2 Group 3 
M
1 
M
2 
M
3 
M
4 
M
5 
M
6 
M
1 
M
2 
M
3 
M
4 
M
5 
M
6 
M
1 
M
2 
M
3 
M
4 
M
5 
M
6 
0.08 / 0 X X X X X X             
2 / 0       X X X X X X       
8 / 0             X X X X X X 
24 / 1 X X X X X X             
48 / 2       X X X X X X       
168 / 7             X X X X X X 
192 / 8 X X X X X X             
216 / 9       X X X X X X       
336 / 14             X X X X X X 
 
3.5.3. Determination of human antibody serum concentrations 
Concentrations of Ustekinumab, Briakinumab, mAb 8 and mAb 9 in murine serum 
were determined by a specific ELISA. 
 
Figure 3-9: ELISA-Design for mAb detection in human serum samples 
Streptavidin-coated MTPs were coated with biotinylated capture reagent (IL-12-Bi). 
Afterwards serum samples and calibration standard were added at various dilutions. Bound 
human antibodies were detected by subsequent incubation with digoxigenin-labeled 
detection antibody (<huFc>-Dig), followed by an incubation with anti-digoxigenin Fab 
fragments conjugated to horseradish peroxidase (<Dig>-POD). ABTS was used as HRP 
substrate to form a colored reaction product. Absorbance of the resulting reaction product 
was read at 405 nm with a reference wavelength at 490 nm and the serum concentrations 
were calibrated against reference standard using a 4-parameter fit. 
Preparation: All serum samples, positive and negative control samples were 
analyzed in duplicates. 5 samples per MTP were analyzed. All dilutions were made 
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in assay buffer (Universal buffer for ELISA). Reagents and buffers were raised to RT 
before usage. Incubation steps were performed under agitation at 500 rpm at RT and 
were followed by 3 washing steps using 300 µL wash buffer (PBS, 0.05% Tween20) 
per well. 
Capture reagent: A streptavidin-coated MTP was coated with 100 µL biotinylated 
IL-12-solution (IL-12-Bi, concentration 100 ng/mL) per well and incubated for 
60 min.  
Sample-Preparation: The calibration standard stock solution (Briakinumab, 
Ustekinumab, mAb 8 or mAb 9, depending on the study) was serially 1:2 diluted 
starting at 12 ng/mL. The resulting calibrator concentrations were 12, 6, 3, 1.5, 0.75, 
0.38, 0.19 and 0 ng/mL. Serum samples of the first five sampling time points (0.08 h 
till 48 h) were diluted 1:5000 and the later time points (168 h till 672 h) were diluted 
1:500 and afterwards serially 1:2 diluted. 
Sample-application: 100 µL of each calibration standard dilution was added to 
column 1 and 2 on the coated MTP (Table 3-3). 100 µL of the sample dilutions as 
well as of positive and negative control samples were added to each well and 
incubated for 60 min.  
Table 3-3: MTP allocation 
5 samples per MTP were analyzed.  
 
1 2 3 4 5 6 7 8 9 10 11 12 
 
calibration 
standard 
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
A 12 ng/mL 
          
B 6 ng/mL 
          
C 3 ng/mL 
          
D 1.5 ng/mL 
          
E 0.8 ng/mL 
          
F 0.4 ng/mL 
          
G 0.2 ng/mL 
          
H 0 ng/mL 
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First detection reagent: A volume of 100 µL of digoxigenin-labeled antibody 
(50 ng/mL <huFc>-Dig) that binds to the Fc region of human IgGs was added to 
each well and incubated for 60 min.  
Second detection reagent: 100 µL of anti-digoxigenin Fab fragments conjugated to 
horseradish peroxidase (15mU/mL <Dig>-POD) were added per well and incubated 
for 60 min. 
Substrate reaction: A volume of 100 µL substrate solution ABTS was added to the 
MTP to each well and the extinction was measured at 405 nm with a reference 
wavelength of 490 nm. Measurement was stopped when the highest calibration 
standard concentration reached an OD of 2.0.  
Calculation: The standard calibration curve was calculated using a 4-parameter fit 
(Wiemer-Rodbard equation    
 
        
 ) of the “XLfit4” software. Sample 
concentrations were calculated from the calibration curve. 
Acceptance criteria: The standard calibration curve must consist of at least 5 values. 
The absorbance of the lowest calibration standard should be below 0.1 OD. For 
sample analysis at least two dilutions of the sample should be within the linear range 
of the standard calibration curve. 
Accuracy: The accuracy of the ELISA was determined to be ± 20% according to 
Roche internal guidelines.  
3.5.4. Pharmacokinetic analysis  
Blood level curves: Mean serum concentrations and standard deviations were 
calculated for each sampling time point. 
Calculation of PK parameters: The pharmacokinetic parameters were calculated 
using WinNonlin™ version 5.3 (Pharsight, USA). Non-compartmental analysis with 
the following settings was used: NCA Model 201, i.v. bolus-input for plasma data. 
The same method has been used by Ling et al. (2009). Pharmacokinetic analysis of 
antibodies is mostly calculated by non-compartmental analysis because antibodies 
In vivo PK study 
53 
 
remain nearly exclusively in the central compartment. Distribution volume (Vd), area 
under the curve (AUC), clearance (Cl) and terminal half-life (T1/2) were calculated. 
Briefly, AUC0-inf values were calculated by logarithmic trapezoidal method due to 
non-linear decrease of the antibodies and extrapolated to infinity using the apparent 
terminal rate constant λz, with extrapolation from the observed concentration at the 
last time point.  
Plasma clearance was calculated as dose rate (D) divided by AUC0-inf. The apparent 
terminal half-life (T1/2) was derived from the equation T1/2 = ln2/λz. 
3.5.5. Statistical analysis 
Outlier test: Outliers in serum concentration analysis were detected using the 
Nalimov outlier test and were excluded from further analysis.  
Statistical significance test: The Tukey’s honest significance test (Tukey’s HSD test) 
was used as statistical test for analysis of statistically significant differences in the 
terminal half-life. 
3.5.6. Detection of drug/ADA immune complexes 
The study samples of the in vivo studies in human FcRn transgenic mice and in FcRn 
knockout mice were tested for the existence of anti-drug antibodies (ADAs). An 
immune complex assay in the ELISA format was used which was based on 
transformation of free ADAs to immune complexes by pre-incubation with excess of 
drug (Figure 3-10). The assay design was modified from Stubenrauch et al. (2012). 
Chemical conjugates of polyclonal human IgG and monoclonal murine IgG were 
prepared as described by Stubenrauch et al. (2010) and used as calibration standard 
and quality control samples (QCs) in the immune complex assay. (Stubenrauch et al. 
2010; Stubenrauch et al. 2012) (Zheng et al. 2012)  
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Figure 3-10: ELISA-Design for detection of drug/ADA immune complexes  
Samples and QCs were preincubated in assay buffer and assay buffer containing the 
antibody. Streptavidin-coated MTPs were coated with biotinylated capture reagent (<huFc>-
Fab’-Bi). Afterwards serum samples and calibration standard were added at various 
dilutions. Bound drug/ADA immune complexes were detected by subsequent incubation 
with POD-labeled detection antibody (<muFc>-POD). ABTS was used as HRP substrate to 
form a colored reaction product. Absorbance of the resulting reaction product was read at 
405 nm with a reference wavelength at 490 nm and the serum concentrations were calibrated 
against calibration standard using a 3-parameter fit. 
Preparation: All serum samples, calibration standards, positive and negative control 
samples were analyzed in duplicates. Per MTP, 16 samples were analyzed. Reagents 
and buffers were raised to RT before usage. All dilutions were made in assay buffer 
(Universal buffer for ELISA). Incubation steps of the streptavidin-coated MTP were 
performed under agitation at 500 rpm at RT and were followed by 3 washing steps 
using 300 µL wash buffer (PBS, 0.05% Tween20) per well. 
Preincubation: The samples, positive QC (calibration standard) and negative QC 
(mouse pool serum, MPS) were incubated with assay buffer and with assay buffer 
containing the antibody at 260 ng/mL for 1 h in a separate preincubation MTP 
(1:50 dilution to obtain 2% mouse serum content) under agitation at 500 rpm at RT.  
Capture reagent: A streptavidin-coated MTP was coated with 100 µL biotinylated 
<huFc>-Fab’-Bi-solution (concentration 1000 ng/mL) per well and incubated for 
30 min.  
Calibration standard preparation: The calibration standard stock solution (chemical 
conjugates of huIgG and muIgG) was diluted in a first step to 200 ng/mL and then 
serially 1:2 further diluted in assay buffer containing 2% MPS. Resulting calibrator 
concentrations in 2% MPS were 200, 100, 50, 25, 12.5, 6.25, 3.13 and 0 ng/mL.  
In vivo PK study 
55 
 
Sample application: 100 µL of each calibration standard dilution was added to 
column 1 and 2 on the coated MTP (Table 3-4). 100 µL of each sample as well as of 
positive and negative control samples were added to each well and incubated for 
60 min.  
Table 3-4: MTP allocation for the drug/ADA immune complex assay 
Per MTP, 16 samples were analyzed in buffer and in buffer containing drug. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
 In 2% MPS In drug-buffer In buffer 
 calibration 
standard 
 
Sample Sample QC Sample Sample QC 
A 200 ng/mL 1 9 
blank 
1 9 
blank 
B 100 ng/mL 2 10 2 10 
C 50 ng/mL 3 11 3 11 
D 25 ng/mL 4 12 4 12 
E 12.5 ng/mL 5 13 Pos.  
contr. 
5 13 Pos.  
contr. F 6.25 ng/mL 6 14 6 14 
G 3.13 ng/mL 7 15 Neg. 
contr. 
7 15 Neg. 
contr. H 0 ng/mL 8 16 8 16 
 
Detection reagent: A volume of 100 µL of POD-labeled antibody (0.4 µg/mL 
<muFc>-POD) that binds to the Fc region of mouse IgGs was added to each well and 
incubated for 60 min. 
Substrate reaction: 100 µL substrate solution ABTS was added to the MTP per well 
and the extinction was measured at 405 nm with a reference wavelength of 490 nm. 
Measurement was stopped when the highest calibration standard concentration 
reached an OD of 2.0.  
Calculation: The obtained data was used for generating the standard calibration 
curve and calculation of the drug/ADA immune complex concentrations of each 
sample. The standard calibration curve was calculated using a 3-parameter fit 
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(equation             ) of the “XLfit4” software and the sample 
concentrations were calibrated against the absorbance-concentration curves of the 
calibration standard.  
Acceptance criteria: The standard calibration curve must consist of at least 5 values. 
The absorbance of the lowest reference standard concentration should be below 
0.1 OD. Samples were classified moderate ADA-positive when the signal was 
threefold higher than the signal of the predose sample. Samples were classified 
severe ADA-positive when the signal was tenfold higher than the signal of the 
predose sample. 
Accuracy: The accuracy of the ELISA was determined to be ± 20%.  
Second model antibody system 
57 
 
3.6. Second model antibody system 
The transferability of the previous results was being tested using a second antibody 
system. Bevacizumab was chosen as second model antibody because the charge 
distribution of Bevacizumab showed no striking positively or negatively charged 
regions. 
Bevacizumab and a Bevacizumab-variant with additional positively charged regions 
in the VL domain were produced. Both antibodies were kindly provided by the 
department of LMR Discovery (Roche Diagnostics GmbH, Mannheim, Germany, 
Site Penzberg). Briefly, synthetic genes were produced for Bevacizumab (Geneart, 
Life technologies, USA) and Bevacizumab-variant was produced by site-directed 
mutagenesis to mutate specific amino acids. The purification process was identical to 
the Briakinumab/Ustekinumab model system and was kindly performed by the 
department of Biochemical & Analyticals Research (Roche Diagnostics GmbH, 
Mannheim, Germany, Site Penzberg). 
The biochemical characterization included measurement of protein concentration, 
size and MW. The methods were performed as described in 3.2.1, 3.2.2 and 3.2.3. 
The functional characterization consisted of analysis of the affinity to human 
vascular endothelial growth factor (VEGF). For quantitative determination of the 
antibodies bound to VEGF, a specific ELISA was performed. 
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Figure 3-11: ELISA-Design for Bevacizumab detection 
Streptavidin-coated MTPs were coated with biotinylated capture reagent (VEGF-Bi). 
Afterwards antibodies were added at various dilutions. Bound human antibodies were 
detected by subsequent incubation with digoxigenin-labeled detection antibody (<huFc>-
Dig), followed by an incubation with anti-digoxigenin Fab fragments conjugated to 
horseradish peroxidase (<Dig>-POD). ABTS was used as HRP substrate to form a colored 
reaction product. Absorbance of the resulting reaction product was read at 405 nm with a 
reference wavelength at 490 nm. 
Preparation: All reagents and buffers were raised to RT before usage. All dilutions 
were made in assay buffer (Universal buffer for ELISA). Incubation steps were 
performed under agitation at 500 rpm at RT and were followed by 3 washing steps 
using 300 µL wash buffer (PBS, 0.05% Tween20) each. 
Capture reagent: A streptavidin-coated MTP was coated with 100 µL biotinylated 
VEGF-solution (VEGF-Bi, concentration 500 ng/mL) per well and incubated for 
60 min.  
Samples: The antibody stock solutions were serially 1:2 diluted starting at 25 ng/mL. 
The resulting concentrations were 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39 and 0 ng/mL. 
100 µL of each antibody dilution as well as of positive and negative control samples 
were added to each well and incubated for 60 min. All samples were analyzed in 
duplicates.  
First detection reagent: A volume of 100 µL of digoxigenin-labeled antibody 
(50 ng/mL <huFc>-Dig) that binds to the Fc region of human IgGs was added to 
each well and incubated for 60 min. 
Second detection reagent: 100 µL of anti-digoxigenin Fab fragments conjugated to 
horseradish peroxidase (25 mU/mL <Dig>-POD) were added to each well and 
incubated for 60 min. 
Substrate reaction: 100 µL of substrate solution ABTS was added to the MTP to 
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each well and the extinction was measured at 405 nm with a reference wavelength of 
490 nm. At an absorbance of 2.0 OD the measurement was stopped.  
Calculation: Using a 4-parameter fit (Wiemer-Rodbard equation    
 
        
 ) of 
the “XLfit4” software the concentration-OD-curves were calculated and compared to 
each other. 
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4. Results 
Abstract 
To investigate the Fab influence on FcRn-mAb interaction, variants of Briakinumab 
and Ustekinumab with cross-over mutations and modified charge distribution in the 
Fab region were analyzed. Using different biochemical methods, it was elucidated 
that the main difference between the mAbs is the charge distribution in the Fv 
domain. Analysis of the FcRn-mAb interactions revealed that an increased extent of 
positively charged regions in the Fv domain resulted in slower dissociation from the 
FcRn. Differences in FcRn-mAb dissociation correlated with in vivo terminal half-
lives in human FcRn transgenic mice, but not in FcRn knockout mice. Using a 
second model antibody indicated that the charge distribution in the Fv domain 
influences FcRn-mAb dissociation in general. 
4.1. Production 
Briakinumab and Ustekinumab are two fully human monoclonal IgG1 antibodies. 
The sequence alignments of the HC and of the LC of both antibodies are shown in  
Figure 4-1.  
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Figure 4-1: Alignment of Briakinumab and Ustekinumab 
Identical and similar amino acids are shown in cyan and dark blue, respectively; VH and VL 
domains are shown in italics; CDRs are marked with an asterisk (*); Single amino acid 
residues mutated to alanines for mAb 7-10 are highlighted in red; a hash (#) denotes amino 
acids in close proximity (≤ 4 Å) to the FcRn in the published FcRn-Fc structure (PDB 4N0U 
(Oganesyan et al. 2014)). 
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Systematically engineered variants of Briakinumab and Ustekinumab with cross-over 
exchanges and modified charge distributions in the Fab region were produced and 
are summarized in Table 4-1. Briefly, structural parts like Fv domains, LCs and 
CDRs were exchanged between Briakinumab and Ustekinumab: mAb 1- 6. Three 
and five basic amino acids in the VH domain of Briakinumab were mutated to 
alanines that resulted in mAb 7 and mAb 8, respectively. MAb 9 is a Briakinumab-
variant with three basic amino acids in the VL domain mutated to alanines. MAb 10 
is a Briakinumab-variant with three basic amino acids in the VL domain and five 
basic amino acids in the VH domain mutated to alanines.  
After expression and purification the final antibody yield was at least of 4 mg and of 
20 mg for antibodies selected to take part in the in vivo studies. After purification 
using protein A chromatography and SEC, all antibodies seemed to be produced 
correctly which was further tested in the biochemical and functional characterization. 
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Table 4-1: Systematically engineered variants of Briakinumab and 
Ustekinumab 
Antibodies conducting PK studies are colorcoded; Briakinumab (orange), Ustekinumab 
(green), mAb 8 (magenta) and mAb 9 (blue). Mutation of basic amino acids is illustrated by 
blue dots; mutation of three amino acids corresponds to 1 blue dot, of five amino acids 
corresponds to 2 blue dots. An asterisk (*) marks mutated amino acid residues according to 
the EU numbering of Kabat. 
Name Description 
 
Briakinumab Briakinumab wild type 
 
Ustekinumab Ustekinumab wild type 
 
mAb 1 Ustekinumab Fv + Briakinumab constant domains 
 
mAb 2 Briakinumab Fv + Ustekinumab constant domains 
 
mAb 3 Ustekinumab HC + Briakinumab LC 
 
mAb 4 Briakinumab HC + Ustekinumab LC 
 
mAb 5 Ustekinumab CDRs on Briakinumab 
 
mAb 6 Briakinumab CDRs on Ustekinumab 
 
mAb 7 Briakinumab  R19
HC
A, K64
HC
A, R83
HC
A* 
 
mAb 8 
Briakinumab  R16
HC
A, R19
HC
A, K57
HC
A, 
K64
HC
A, R83
HC
A* 
 
mAb 9 Briakinumab  R27
LC
A, R55
LC
A, R94
LC
A* 
 
mAb 10 
Briakinumab  R16
HC
A, R19
HC
A, K57
HC
A, 
K64
HC
A, R83
HC
A, R27
LC
A, R55
LC
A, R94
LC
A* 
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4.2. Biochemical characterization 
Antibodies were biochemically characterized to test if antibodies were produced 
correctly and to find differences between Briakinumab and Ustekinumab that could 
explain the reported differences in PK. The biochemical characterization of 
Briakinumab and Ustekinumab is shown in detail. Summarized results of the 
biochemical characterization of all mAbs are presented in Table 4-2 and Table 4-10. 
4.2.1. Determination of mAb concentration 
The protein concentration of Briakinumab and Ustekinumab samples used in this 
work was determined at 2.36 and 2.67 mg/mL, respectively. The concentrations of 
all mAbs are summarized in Table 4-2. 
4.2.2. Determination of mAb molecular weight by CE-SDS 
Briakinumab and Ustekinumab have molecular weights of about 155 kDa as 
measured by CE-SDS which is comparable with the theoretical molecular weight 
calculated by the protein sequence of 143 and 146 kDa, respectively (Figure 4-2). 
Reduced HCs have nearly identical molecular weights of about 58-59 kDa and the 
LCs vary between ~33 kDa of Briakinumab and ~26 kDa of Ustekinumab due to 
different LC-isotypes. The theoretical MWs for HCs and LCs of both antibodies are 
49 and 23 kDa, respectively, and are in agreement with the determined MWs. 
Reduced HCs and LCs show in total a higher molecular weight than the non-reduced 
antibodies which could be caused by sterical effects of the free disulfide strands. 
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Figure 4-2: Purity and molecular weight  
Gel-like images of the intact mAbs and of HCs and LCs after DTT-reduction. 
The purity of the intact antibody of Briakinumab and Ustekinumab is 92 and 84%, 
respectively. The occurred impurities of both mAbs are mainly a single LC and a 
combination of two heavy chains and one light chain. This can also be confirmed by 
the ratio of Briakinumab’s intact HCs and LCs of 67 and 33%, respectively. The HC 
ratio is twice as high as the LC ratio which is due to the higher MW of the HC and a 
therefore higher fluorescence intensity in the electropherogram. Also, Ustekinumab’s 
HCs and LCs have intact chains of 64 and 32%, respectively. Therefore the ratio of 
minor forms being neither intact HC nor LC is 0 and 4% for Briakinumab and 
Ustekinumab, respectively. 
The MW distribution of all mAbs is summarized in Table 4-2. The MW of each mAb 
is in agreement with the theoretical value and the purity of the MW species is also 
high. 
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4.2.3. Determination of mAb size by SEC 
Briakinumab and Ustekinumab show monomer contents of at least 99%. The content 
of aggregates and LMWs is very small (< 1%). Briakinumab shows a slightly longer 
retention time (Figure 4-3) which might indicate an interaction with the column 
matrix or a slightly smaller hydrodynamic radius. 
 
Figure 4-3: SEC chromatogram  
Sample peaks are normalized to Briakinumab’s main peak. 
The monomer content of all mAbs is summarized in Table 4-2. The content of 
aggregates and LMWs is very small (< 3%). 
4.2.4. Determination of mAb hydrophobicity 
Hydrophobicity of proteins is not an absolute molecule property and depends on 
numerous factors including protein sequence and structure. To classify antibodies 
with respect to potential hydrophobic interactions, hydrophobicity was determined 
relative to two low and high hydrophobic antibodies. These low and high 
hydrophobic reference samples (RS) were defined as 0 and 100% hydrophobic, 
respectively. Briakinumab elutes 2.2 min after Ustekinumab (Figure 4-4) indicating a 
slightly higher hydrophobicity, but according to this hydrophobicity scale, 
Briakinumab and Ustekinumab are both low hydrophobic. 
Biochemical characterization 
67 
 
 
Figure 4-4: HIC chromatogram 
Low and high hydrophobic RS define the hydrophobic range. Sample peaks are normalized 
to the low hydrophobic RS peak. 
Table 4-2 summarizes the hydrophobic profile of all mAbs. Variants with cross-over 
exchanges show a relative hydrophicity of ≤ 13%. Antibodies with mutation of three 
basic amino acids to alanines in the VH and VL domains have relative hydrophobic 
values of 13 and 16%, respectively. Mutation of five basic amino acids in the VH 
domain results in 24% hydrophobicity. The hydrophobicity is increased to 34% by 
mutation of three and five basic amino acids in VL and VH domains, respectively. 
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Table 4-2: Overview biochemical characterization of all mAbs 
The concentration is given as the average of 3 measurements. Monomer contents are 
determined by integration of the SEC chromatogram. Purity of antibody species is 
determined by CE-SDS of the intact mAbs and after DTT-reduction. The hydrophobicity is 
presented relative to low and high hydrophobic RS. 
Sample 
Conc. 
[mg/mL] 
SEC [%] CE-SDS [%] Hydro-
phobicity 
[%] 
Monomer 
content 
Intact 
mAb 
HC LC 
Briakinumab 2.36 99.9 92 67 33 7 
Ustekinumab 2.67 99.0 84 64 32 -1 
mAb 1 2.32 99.4 74 66 31 -6 
mAb 2 1.66 98.1 91 64 32 8 
mAb 3 2.14 99.3 80 66 28 8 
mAb 4 2.10 99.8 82 64 32 -4 
mAb 5 3.03 99.5 90 70 30 13 
mAb 6 0.40 97.1 95 66 32 12 
mAb 7 2.90 97.2 85 65 33 13 
mAb 8 3.10 98.9 85 64 34 24 
mAb 9 3.15 99.1 80 70 29 16 
mAb 10 4.08 98.6 88 70 28 34 
 
4.2.5. Analysis of stressed mAbs 
Stress tests were performed to analyze the protein stability and evaluate the tendency 
to aggregate formation. The concentrations of the samples before and after 6 freeze-
thaw cycles are nearly identical (Table 4-3). The monomer content and MW of the 
stressed samples are comparable to the ones of the unstressed samples (compare with 
4.2.2 and 4.2.3), therefore Briakinumab and Ustekinumab are resistant to freeze-thaw 
stress. 
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Table 4-3: Protein concentration, size and MW after freeze-thaw stress 
Protein concentration was measured before and after freeze-thaw stress and is given as the 
average of 3 measurements. Monomer contents are determined by integration of the SEC 
chromatogram. Purity of antibody species is determined by CE-SDS of the intact mAbs and 
after DTT-reduction. 
Sample 
Concentration 
[mg/mL] 
SEC     
[%] 
CE-SDS                                       
[%] 
Cycle 0 Cycle 6 
Monomer 
content 
Intact 
mAb 
HC LC 
Briakinumab 1.0 0.99 99.7 90 65 35 
Ustekinumab 1.0 0.95 98.7 82 66 34 
 
The protein concentration, size and MW of the samples after accelerated temperature 
stress are comparable to the ones of the unstressed samples (compare with 4.2.2 and 
4.2.3) indicating that both mAbs have a stable protein structure in different buffers 
and under different temperature conditions. Therefore both mAbs are resistant to 
storage-temperature stress. 
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Table 4-4: Protein concentration, size and MW after storage-temperature 
stress 
Protein concentration, size and MW distribution were measured after incubation under 
different buffer and temperature conditions for 7 days. Protein concentration is given as the 
average of 3 measurements. Monomer contents are determined by integration of the SEC 
chromatogram. Purity of antibody species is determined by CE-SDS of the intact mAbs and 
after DTT-reduction. 
Sample 
Storage condition 
Conc. 
[mg/mL] 
SEC      
[%] 
CE-SDS                                       
[%] 
Buffer 
Temp. 
[°C] 
Monomer 
content 
Intact 
mAb 
HC LC 
Briakinumab 
His/NaCl, 
pH 6.0 
- 80 0.98 99.8 84 62 32 
His/NaCl, 
pH 6.0 
37 0.94 99.7 84 65 32 
PBS, 
pH 7.4 
- 80 0.99 99.8 80 64 31 
PBS, 
pH 7.4 
37 0.97 99.5 77 61 31 
Ustekinumab 
His/NaCl, 
pH 6.0 
- 80 0.96 99.6 85 68 31 
His/NaCl, 
pH 6.0 
37 0.90 99.4 85 65 28 
PBS, 
pH 7.4 
- 80 0.99 99.3 82 68 30 
PBS, 
pH 7.4 
37 0.93 99.4 82 68 30 
 
The monomer contents of both mAbs were still ≥ 99%, therefore no significant 
aggregate formation was observed due to freeze-thaw or storage-temperature stress. 
Both stress-tests showed that Briakinumab and Ustekinumab are unaffected by 
temperature and storage conditions, thereby demonstrating high protein stability. 
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4.2.6. Determination of mAb isoelectric point 
The isoelectric points of Briakinumab and Ustekinumab are given in Table 4-5. 
Calculated and measured pIs are in good agreement; therefore the pIs of the mAb 
variants were subsequently calculated only. 
Table 4-5: Isoelectric points of Briakinumab and Ustekinumab 
The isoelectric points were measured and calculated using cIEF and GPMAW, respectively.  
Sample Measured pI Calculated pI 
Briakinumab 9.6 9.7 
Ustekinumab 9.3 9.4 
 
The isoelectric points of variants with cross-over exchanges (mAb 1-6) range 
between pI 9.4 and 9.6. MAbs with mutated basic amino acids to alanines range 
between 9.0 and 9.4 illustrating that smaller positively charged regions slightly 
reduce the pI. To sum up, all mAbs are in a narrow pI-range between 9.0 and 9.7 
(Table 4-6).  
In addition to the isoelectric points, the net charges of the Fv domains at lysosomal 
pH 6.0 and at physiological pH 7.4 were calculated and summarized in Table 4-6. 
Due to cross-over exchanges and modified charge distribution, the net charges of the 
respective domains are affected. For example, mAbs with less basic amino acids in 
the VH have reduced net charges in this domain.  
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Table 4-6: Net charges of all mAbs 
The isoelectric points were calculated assuming all cysteines are involved in disulfide 
bridges. The net charge [e
-
] of VH, VL and Fv domains at pH 6.0 and pH 7.4 were calculated 
assuming all cysteines are involved in disulfide bridges.  
 
 
4.2.7. Charge distribution analysis 
The charge distribution in the Fv domain of all mAbs as well as of the FcRn was 
calculated using a 3D model and expert software by Dr. Hubert Kettenberger 
(Biochemical & Analyticals Research, Roche Diagnostics GmbH, Mannheim, 
Germany, Site Penzberg). 
Using the published crystal structure of Ustekinumab (Luo et al. 2010) and a 
homology model of Briakinumab, it was observed that Briakinumab exhibits a non-
uniform charge distribution at physiological pH of 7.4. Briakinumab shows a large 
positively charged region on the Fab region which is absent in Ustekinumab (Figure 
4-5). This positively charged region spans the VH and the VL domains. 
 
calc. pI 
(IgG)
q (VL) 
pH 6
q (VL) 
pH 7.4
q (VH) 
pH 6
q (VH) 
pH 7.4
q (Fv) 
pH 6.0
q (Fv) 
pH 7.4
Briakinumab 9.7 3.8 3.0 6.4 4.3 10.2 7.3
Ustekinumab 9.4 2.1 1.9 3.1 2.9 5.2 4.9
mAb 1 9.5 2.1 1.9 3.1 2.9 5.2 4.9
mAb 2 9.4 3.8 3.0 6.4 4.3 10.2 7.3
mAb 3 9.5 3.8 3.0 3.1 2.9 6.9 6.0
mAb 4 9.5 2.1 1.9 6.4 4.3 8.4 6.2
mAb 5 9.6 2.1 1.9 4.1 3.9 6.1 5.9
mAb 6 9.4 3.9 3.0 5.4 3.3 9.2 6.3
mAb 7 9.4 3.8 3.0 3.4 1.3 7.2 4.3
mAb 8 9.3 3.8 3.0 1.4 -0.7 5.2 2.3
mAb 9 9.4 0.8 0.0 6.4 4.3 7.2 4.3
mAb 10 9.0 0.8 0.0 1.4 -0.7 2.2 -0.6
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Figure 4-5: Charge distribution of Briakinumab and Ustekinumab 
Isopotential surfaces of the proteins protonated at pH 7.4 and contoured at 2 kBT/e; blue: 
positive; red: negative. The view focuses on the CDRs. Briakinumab: Light and heavy chains 
are shown in yellow and orange, respectively. Ustekinumab: Light and heavy chains are 
colored in light and dark green, respectively.  
Isopotential surfaces of all mAbs are shown in Figure 4-6. The charge distribution is 
strongly affected by cross-over exchanges. MAb 1 and mAb 4 both containing 
Ustekinumab’s VL domain show a smaller positively charged region in the Fab than 
mAb 2 and mAb 3 bearing Briakinumab’s VL domain. MAb 7 and mAb 8, which 
have basic amino acids in the VH domain mutated to alanines, show a smaller 
positively charged region in this domain. MAb 9 which has basic amino acids in the 
VL domain mutated to alanines illustrates a smaller positively charged region in this 
area. MAb 10 that has basic amino acids in VH and VL domains mutated to alanines 
shows smaller positively charged regions in the Fv domain. 
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Figure 4-6: Charge distribution of all mAbs 
Isopotential surfaces of the proteins protonated at pH 7.4 and contoured at 2 kBT/e; blue: 
positive; red: negative. The light and heavy chains are shown in light and dark grey, 
respectively. The view focuses on the CDRs. 
Using the recently published crystal structure of human FcRn (Oganesyan et al. 
2014), it was observed that FcRn possesses an extended negatively charged region on 
one side of the receptor at physiological pH of 7.4. On the other receptor side, 
positively charged regions were observed (Figure 4-7) which are not involved in 
cognate Fc binding. 
 
Figure 4-7: Charge distribution of the FcRn 
Isopotential surface at pH 7.4 of a human FcRn (cyan) in complex with human 
β2 microglobulin (green) contoured at 1 kBT/e; blue: positive; red: negative. A different 
contour level (1 kBT/e instead of 2 kBT/e) is used for clarity. Views of the left and right 
image are related by a rotation about a vertical axis. The Fc domain is shown as ribbons for 
clarity and was not considered in isopotential calculation.  
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4.2.8. IdeS cleavage 
The IdeS cleavage was controlled by CE-SDS and analytical SEC. The IdeS-cleaved 
antibodies have molecular weights of about 108 kDa and 38 kDa (Figure 4-8) which 
corresponds to the F(ab’)2 part (literature data 110 kDa) and the Fc fragments 
(literature data 31 kDa), respectively (Loomes et al. 1993; von Pawel-Rammingen et 
al. 2002). The absence of mAb bands indicates complete cleavage. The Fc fragment 
is detected as a faint band which is typical for glycoproteins on CE-SDS.  
Intact F(ab’)2 part and Fc monomers of Briakinumab show high purity of 61 and 
32%, respectively. Ustekinumab’s F(ab’)2 part and Fc monomers have pure 
fragments of 64 and 31%, respectively. Therefore the ratio of minor forms being 
neither intact F(ab’)2  nor Fc monomer is small with 7 and 5% for Briakinumab and 
Ustekinumab, respectively. 
 
Figure 4-8: Molecular weight of IdeS-cleaved mAbs 
Gel-like images of the intact mAbs and after IdeS-cleavage into F(ab’)2 and Fc fragments. 
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These observations were further confirmed by the SEC-results which also provide 
two fractions at about 110 kDa and 33 kDa and no residual intact antibody. 
Briakinumab’s F(ab’)2 part shows a slightly longer retention time which might 
indicate an interaction with the column matrix or a slightly smaller hydrodynamic 
range (Figure 4-9).  
 
Figure 4-9: Apparent molecular weight of Briakinumab and Ustekinumab 
after IdeS cleavage. 
Sample peaks are normalized to Briakinumab’s Fc fragment peak. 
The cleavage was therefore successful, the F(ab’)2 region and the Fc fragments were 
tested for FcRn interactions (4.4.2.2). 
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4.3. Functional characterization 
The functional characterization includes analysis of the interaction with the target 
(human IL-12) to test if Briakinumab and Ustekinumab were produced correctly and 
the target binding is still functional. The mAb variants were modified in the Fab 
region and it is tested if these modifications alter the target binding. Furthermore the 
interaction of the antibodies used in the mouse PK study with mouse IL-12/-23 are 
analyzed to exclude target-mediated clearance effects in the mouse study. In 
addition, binding levels to mouse Fcɣ receptor I (muFcɣRI) are measured because 
stronger binding to mouse FcɣRI could lead to a faster decrease in a PK study due to 
faster uptake into antigen presenting cells. 
4.3.1. Interaction with human IL-12 
Briakinumab, Ustekinumab and the variants have structural differences in the Fab 
region that can influence IL-12 binding, therefore the results of all mAbs are 
presented in detail. 
4.3.1.1. ELISA 
The absorbance-concentration curves of the variants with cross-over exchanges 
(mAb 1-6) and with modified charge distribution (mAb 7-10) are shown in Figure 
4-10 and Figure 4-11, respectively. The concentration of each mAb was calculated 
using the fit of the Briakinumab calibration curve to obtain IL-12 binding relative to 
Briakinumab (Briakinumab = 100%). Binding differences of ≤ 30% were assessed to 
show similar binding to IL-12 as Briakinumab, differences of ≥ 30% indicate 
reduced binding to IL-12. Briakinumab, Ustekinumab and mAbs with exchanged Fv 
domains (mAb 1 and mAb 2) show similar IL-12 binding profiles. The binding of 
Briakinumab, Ustekinumab and mAb 2 ranges in a 20% window and of mAb 1 in a 
30% window. MAbs with exchanged LCs (mAb 3 and mAb 4) and mAbs with 
exchanged CDRs (mAb 5 and mAb 6) do not bind to IL-12.  
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Figure 4-10: IL-12 interaction of Briakinumab, Ustekinumab and mAb 1-6 
The absorbance-concentration curves of Briakinumab, Ustekinumab and mAbs with cross-
over exchanges. The absorbance-concentration curves of mAb 3-5 overlap. 
Briakinumab variants with modified charge distribution (mAb 7–9) bind IL-12 in a 
range of 30% relative to Briakinumab indicating similar IL-12 binding. Only mAb 10 
shows reduced IL-12 binding with 63% binding compared to Briakinumab.  
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Figure 4-11: IL-12 interaction of Briakinumab, Ustekinumab and mAb 7-10 
The absorbance-concentration curves of Briakinumab, Ustekinumab and mAb 7-10. 
4.3.1.2. SPR 
SPR was used to confirm the results of the target specific ELISA. Ustekinumab and 
Briakinumab have nearly identical association rate constants (ka) (ka (Briakinumab) 
        1/Ms vs. ka (Ustekinumab)        1/Ms). The dissociation of IL-12 
and the mAbs is very slow (Figure 4-12), therefore calculation of the dissociation 
rate constant (kd) and subsequently of the equilibrium dissociation constant (KD) may 
differ from the actual values. Despite the limitation of the method in this setting, the 
calculated values can give a general impression and can be used to confirm the 
ELISA results. Briakinumab and Ustekinumab bind IL-12 with high affinity and the 
KD is in a low nM-range (KD (Briakinumab) = 0.07 nM vs. KD (Ustekinumab) 
= 0.2 nM). The measured affinity of Briakinumab with ka, kd and KD values of 
      1/Ms,        1/s and 70 pM, respectively, are in agreement with literature 
data (ka       1/Ms, kd          1/s, KD = 100 pM) (Ding et al. 2008). The 
high affinity of Ustekinumab to IL-12 is also described in literature (Weber and 
Keam 2009). 
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Figure 4-12: SPR sensorgrams (concentration series) of Briakinumab binding 
to IL-12. 
Sensorgrams were fitted to a steady state affinity model; fitted curves are shown in dark 
grey. IL-12 association and dissociation was detected in a rising concentration series. 
Table 4-7 summarizes the calculated kinetic parameters of the target interaction. 
MAbs with exchanged Fv domains (mAb 1 and mAb 2) and mAbs with modified 
charge distributions (mAb 7-10) have affinities to IL-12 similar to Briakinumab and 
Ustekinumab. MAb 3 and mAb 5 do not bind to IL-12 and mAb 4 and mAb 6 show 
very weak binding to IL-12. The data is in agreement with the ELISA results.  
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Table 4-7: SPR parameters of mAbs and IL-12 
KD, ka and kd were calculated using steady state affinity.  
Sample ka [1/Ms] kd [1/s] KD [nM] 
Ustekinumab                  0.20 
Briakinumab                  0.07 
mAb 1                  0.24 
mAb 2                  0.25 
mAb 3 no binding no binding no binding 
mAb 4         2.3 191 
mAb 5 no binding no binding no binding 
mAb 6                  9.62 
mAb 7                  0.08 
mAb 8                  0.07 
mAb 9                  0.01 
mAb 10                  0.01 
 
4.3.2. Interaction with IL-12 and IL-23 of different species 
The binding levels of the mAbs used in the in vivo study (Briakinumab, 
Ustekinumab, mAb 8 and mAb 9) to recombinant human IL-12, human IL-23, mouse 
IL-12 and mouse IL-23 were analyzed. The approach to determine binding levels can 
be used if a general evaluation is sufficient information, because binding levels do 
not provide information about the binding kinetics. All mAbs showed RU binding 
levels to human IL-12 and human IL-23, but hardly any to mouse IL-12 and mouse 
IL-23. This finding is in accordance with literature data (Luo et al. 2010; Traczewski 
and Rudnicka 2012) and confirms that target-mediated clearance effects can be 
excluded when performing a mouse PK study. 
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Figure 4-13: Binding levels to IL-12/-23 of different species 
Binding levels to recombinant human IL-12, human IL-23, mouse IL-12 and mouse IL-23. 
4.3.3. Interaction with mouse FcɣRI 
The binding levels of the mAbs studied in the in vivo experiments (Briakinumab, 
Ustekinumab, mAb 8 and mAb 9) to muFcɣRI were determined. Briakinumab 
showed higher binding levels than Ustekinumab, mAb 8 and mAb 9. Higher binding 
levels may indicate a stronger interaction with mouse FcɣRI resulting in faster 
uptake into antigen presenting cells and subsequently in a faster serum concentration 
decrease in a PK study. To better analyze this interaction more appropriate tools 
would be needed to get stronger data. 
 
 
Figure 4-14: Binding levels to muFcɣRI. 
Binding levels of the antibodies used in the in vivo study to mouse FcɣRI. 
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4.4. FcRn-mAb interaction 
The FcRn-mAb interaction is studied to elucidate the contribution of the FcRn-IgG 
interaction on PK. The interaction consists of two parts, which were analyzed 
separately. The FcRn-mAb interaction analyzed at pH 6.0 provides information 
about the affinity and at higher pH values about the dissociation of the FcRn-mAb 
complex. 
4.4.1. FcRn-mAb affinity at pH 6.0 
The KD was calculated relative to Ustekinumab (Ustekinumab = 1.0). From the KD 
values, the affinity of the mAbs to FcRn was assessed to be similar to the 
Ustekinumab-FcRn affinity if differences were smaller than one decimal power to 
the Ustekinumab-FcRn KD. KDs were rated as different if KD differences were bigger 
than one decimal power to the Ustekinumab-FcRn KD. The FcRn affinities at pH 6.0 
fell in a narrow range for all mAbs. Briakinumab had a relative KD of 0.2 and the 
variants ranged between Briakinumab and Ustekinumab except for mAb 10 that had 
a relative KD of 1.1 (Table 4-8).  
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Table 4-8: Relative KDs of all mAbs to FcRn 
Relative KD values (Ustekinumab = 1) are presented as the mean (n = 3) ± standard 
deviation. 
Sample rel. KD 
Ustekinumab 1 
 
Briakinumab 0.2 ± 0.07 
mAb 1 1.0 ± 0.22 
mAb 2 0.3 ± 0.19 
mAb 3 0.2 ± 0.06 
mAb 4 0.5 ± 0.08 
mAb 5 0.9 ± 0.16 
mAb 6 0.4 ± 0.17 
mAb 7 0.2 ± 0.03 
mAb 8 0.4 ± 0.07 
mAb 9 0.4 ± 0.04 
mAb 10 1.1 ± 0.09 
 
4.4.2. FcRn-mAb dissociation 
The dissociation of FcRn and the mAbs was analyzed by SPR and FcRn affinity 
chromatography. 
4.4.2.1. FcRn-mAb dissociation using SPR 
KD values were evaluated as follows: KD values below 1 µM were assessed to show 
moderate affinity, between 1-5µM to show weak affinity and above 5µM to show no 
binding to FcRn. Briakinumab and Ustekinumab showed similar affinities at pH 6.0. 
Ustekinumab showed very weak affinity at pH 6.6 and no affinity at pH 6.8. In 
contrast, Briakinumab showed a moderate affinity up to pH 6.8, weak affinity at 
pH 7.0 and no binding at pH 7.2 (Table 4-9). 
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Table 4-9: KD of Briakinumab and Ustekinumab to FcRn 
KDs were calculated using buffers with increasing pH values. KD values higher than 5 µM 
were classified as no binding. 
 Briakinumab KD 
[µM] 
Ustekinumab KD 
[µM] 
pH 6.0 0.09 0.39 
pH 6.4 0.10 1.00 
pH 6.6 0.36 3.10 
pH 6.8 0.60 no binding 
pH 7.0 4.20 no binding 
pH 7.2 no binding no binding 
 
4.4.2.2. FcRn affinity chromatography using a pH gradient 
For analysis of the FcRn-mAb dissociation at physiological pH the FcRn affinity 
chromatography was used because SPR does not provide precise information about 
the dissociation pH. The FcRn affinity chromatography closely mimics physiological 
conditions for the dissociation between FcRn and IgGs. The principle is shown in 
Figure 4-15. The method describes a chromatography method that uses a column 
packed with high concentration of FcRn. Antibodies bind at acidic pH of 5-6 to the 
FcRn and afterwards elute from the FcRn column due to increasing pH. Therefore 
the FcRn affinity chromatography gives precise information about the pH 
dependency of the FcRn-IgG dissociation. 
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Figure 4-15: Principle FcRn affinity chromatography 
IgGs bind to the FcRn at pH 5.5 and are eluted by a linear pH gradient from pH 5.5 to 8.8. 
Retention times and elution pHs can be measured.  
Briakinumab and Ustekinumab showed striking retention time differences. 
Briakinumab eluted after 93.7 min, whereas Ustekinumab eluted after 84.4 min 
(Figure 4-16). These retention times correspond to elution pHs of 7.9 and 7.4 for 
Briakinumab and Ustekinumab, respectively. These differences in FcRn-mAb 
dissociation are in agreement with the SPR results (4.4.2.1). Using both methods, the 
interaction between Briakinumab and FcRn seems to be stronger at higher pH values 
than between Ustekinumab and FcRn. 
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Figure 4-16: FcRn column chromatogram of Briakinumab and Ustekinumab 
Sample peaks are normalized to Briakinumab’s main peak. 
To investigate whether the retention time differences of Briakinumab and 
Ustekinumab are influenced by the Fab region, both antibodies were cleaved using 
IdeS. The F(ab’)2 region did not bind to FcRn and eluted in the first minutes after 
injection indicating that the Fc region is indispensable for the interaction with FcRn. 
The cleaved Fc regions of Briakinumab and Ustekinumab eluted after 85.6 min 
(elution pH of 7.5) and 85.2 min (elution pH 7.4), respectively (Figure 4-17). The 
nearly identical retention times of the IdeS-cleaved Fc regions of Briakinumab and 
Ustekinumab indicate the negligible role of the Fc region in this setting and point 
toward the role of the Fab region on FcRn-mAb dissociation. 
 
Figure 4-17: FcRn column chromatogram of IdeS-cleaved Fc regions 
Sample peaks are normalized to Briakinumab’s main peak. 
To further elucidate which structural elements of the Fab region are mainly 
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influencing FcRn column retention times, the antibody variants mAb 1 and mAb 2 
were analyzed for FcRn column binding (Figure 4-18). MAb 1, which bears the Fv 
domain of Ustekinumab on the constant parts of Briakinumab, had the same FcRn 
column retention time as Ustekinumab. MAb 2, containing the Fv domain of 
Briakinumab on the Ustekinumab constant domains, eluted close to Briakinumab 
indicating that the Fv domain influences the interaction with FcRn. 
 
Figure 4-18: FcRn column chromatogram of Fv-exchanged variants 
Sample peaks are normalized to Briakinumab’s main peak. 
The influence of the LCs was analyzed using mAb 3 and mAb 4. MAb 3, comprising 
the HCs of Ustekinumab and the LCs of Briakinumab, eluted close to Briakinumab 
(Figure 4-19). MAb 4, containing Ustekinumab LCs and Briakinumab HCs, eluted 
close to Ustekinumab revealing the strong impact of the LC on FcRn-mAb 
interaction. 
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Figure 4-19: FcRn column chromatogram of LC-exchanged variants 
Sample peaks are normalized to Briakinumab’s main peak. 
To study the influence of the CDRs on FcRn dissociation, mAb 5 and mAb 6 were 
tested for FcRn column interaction (Figure 4-20). MAb 5, that has Ustekinumab 
CDRs grafted on Briakinumab, has a retention time shift close to the retention time 
of Ustekinumab. The opposite was not observed to the same extent. MAb 6, 
Briakinumab CDRs on Ustekinumab, described an elution profile which was still 
close to that of Ustekinumab. 
 
Figure 4-20: FcRn column chromatogram of CDRs-exchanged variants 
Sample peaks are normalized to Briakinumab’s main peak. 
The results so far suggested that the light chain CDRs of Briakinumab have the main 
influence on FcRn column retention times. To confirm this hypothesis the FcRn-
mAb interaction was analyzed using mAbs bound to their target. By binding to the 
target, the CDRs of the mAbs are shielded, thereby repressing the influence of the 
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CDRs on the FcRn-mAb interaction. Briakinumab as well as Ustekinumab bind 
human IL-12 with high affinity, therefore the mAb-IL-12 complex is supposed to be 
very stable. 
Ustekinumab and Ustekinumab-IL-12 complex have identical FcRn column retention 
times of 82.8 minutes (Figure 4-21). Ustkinumab-IL-12 complex shows a fronting 
before the main peak, but the main peak retention time is identical to unbound 
Ustekinumab. 
 
Figure 4-21: FcRn column chromatogram of Ustekinumab-IL-12 complex  
Sample peaks are normalized to Ustekinumab’s main peak. 
The Briakinumab-IL-12 complex assembled using an excess of Briakinumab shows 
three fractions with different FcRn column retention times. The main peak has the 
same retention time as Briakinumab of about 93 min (Figure 4-22). Therefore it was 
assumed that the main fraction is probably unbound Briakinumab. Prepeak 1 and 
prepeak 2 elute at 85 min and 80 min, respectively. Prepeak 1 could be a fraction 
including Briakinumab with one bound IL-12, by which the CDRs of one Fab-arm 
are shielded while the other one remains unshielded. Prepeak 2 could be a fraction 
including Briakinumab with two bound IL-12, by which CDRs of both Fab-arms are 
shielded.  
This assignment was further confirmed by the FcRn column profile of the 
Briakinumab-IL-12 complex assembled using an IL-12 excess. The IL-12 excess 
shifts the balance towards a complex of two IL-12 molecules binding to one 
Briakinumab molecule. The FcRn column retention times are nearly identical to the 
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ones of the prepeak 2 of the Briakinumab-IL-12 complex consisting of Briakinumab-
excess, therefore prepeak 2 presents most likely Briakinumab bound to two IL-12 
molecules. 
 
Figure 4-22: FcRn column chromatogram of Briakinumab-IL-12 complex  
Sample peaks are normalized to the main peak of Briakinumab-IL-12 complex assembled 
using IL-12 excess. 
By binding to the target and thereby shielding the CDRs of the antibodies the 
Briakinumab-FcRn interaction is more affected than the Ustekinumab-FcRn 
interaction. Shielding the CDRs of Ustekinumab does not influence the interaction 
with FcRn. In contrast, repressing the influence of the CDRs on the FcRn-
Briakinumab interaction, by binding to the target, results in faster dissociation from 
the FcRn.  
To study the nature of the FcRn-mAb interaction further, the FcRn column retention 
times were measured in the presence of increasing salt concentrations in both eluents 
of the pH gradient system. Charge-mediated interactions are thereby weakened, 
whereas hydrophobic interactions are strengthened under high ionic strength 
conditions. The FcRn column retention time of Ustekinumab remained essentially 
unaffected by higher salt concentrations (Figure 4-23). In contrast, the retention time 
of Briakinumab was shortened in the presence of salt in a manner roughly 
proportional to the inverse square root of the ionic strength (Figure 4-24) as 
suggested by the Debye-Hückel law of charge screening (Israelachvili 1985). In 
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conclusion, a significant part of the excessive FcRn-Briakinumab interaction seems 
to be charge-mediated. 
 
Figure 4-23: FcRn column chromatogram under higher ionic strength 
conditions 
Sample peaks are normalized to the main peak of Briakinumab using 140 mM NaCl. 
 
 
Figure 4-24: Salt-dependent FcRn-mAb interaction of Briakinumab and 
Ustekinumab 
Retention times are plotted against the salt concentration. A regression line is generated for 
Ustekinumab’s data. Briakinumab’s data are fitted to an inverse square root function with 
  √        (r² = 0.898). 
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To further study the charge-mediated FcRn-mAb interaction, Briakinumab variants 
with smaller positively charged regions in the VH and VL domain were analyzed for 
FcRn-mAb dissociation behavior. 
FcRn column retention times seemed to be mainly influenced by the VL domain. It 
needed to be studied if the large positively charged region in the VH domain of 
Briakinumab (Figure 4-5) has also an influence on FcRn-mAb dissociation. 
Therefore the FcRn-mAb dissociation was analyzed using two variants of 
Briakinumab with smaller positively charged regions in the VH domain, mAb 7 and 
mAb 8. Both mAbs showed shorter retention times compared to Briakinumab 
(Figure 4-25). This confirms the hypothesis that a Briakinumab-variant with smaller 
positively charged region dissociates faster from FcRn than Briakinumab. The 
differences in retention time are not as large as with exchanged LCs or Fv domains, 
but they nevertheless seem to influence FcRn-mAb interaction. MAb 7 with three 
mutated amino acids and mAb 8 with five mutated amino acids showed nearly 
identical retention times of 90.4 and 90.1 min, respectively, indicating that additional 
mutation of R16
HC
A and R57
HC
A does not influence FcRn-mAb dissociation. 
 
Figure 4-25: FcRn column chromatogram of Briakinumab-variants with 
modified charge distribution in the VH domain 
Sample peaks are normalized to Briakinumab’s main peak. 
The influence of charged regions in the VL on FcRn-mAb interaction was analyzed 
using the variants with smaller positively charged regions in the VL domain. A strong 
retention time shift from Briakinumab in the direction of Ustekinumab was observed 
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for mAb 9, that is a Briakinumab-variant with three positively charged residues in 
the VL domain mutated to alanines (Figure 4-26). Additional mutation of 5 basic 
amino acids in the VH domain of Briakinumab (mAb 10) shortened FcRn column 
retention times even more, so that mAb 10 had almost the same retention time as 
Ustekinumab. 
 
Figure 4-26: FcRn column chromatogram of Briakinumab-variants with 
modified charge distribution in the VH and VL domain 
Sample peaks are normalized to Briakinumab’s main peak. 
In summary, FcRn affinity chromatography of the engineered variants showed that 
antibodies with the same Fv domain and the same LC elute at nearly identical FcRn 
column retention times. Furthermore, grafting Ustekinumab CDRs on Briakinumab 
(mAb 5) shifts the retention time close to that of Ustekinumab. Combining these 
results leads to the conclusion that the light chain variable domain (VL), and for 
Briakinumab especially the light chain CDRs, provide the main influence on the 
FcRn-mAb interaction.  
FcRn column retention times were compared with net charges of the Fv domains at 
pH 6.0 or pH 7.4, hydrophobicity, isoelectric points and the extent of charged regions 
in the Fv structures (Table 4-10) to find the parameter that mainly influences FcRn-
mAb dissociation. 
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Table 4-10: FcRn affinities, calculated net charges and hydrophobicity 
Antibodies are sorted according to the FcRn column retention times. Isopotential surfaces of 
the proteins protonated at pH 7.4 and contoured at 2 kBT/e. The KD was normalized to the KD 
of Ustekinumab. Relative KD values (Ustekinumab = 1) are presented as the mean (n=3) ± 
standard deviation. The net charge [e
-
] of VH, VL and Fv domains at pH 6.0 and pH 7.4 were 
calculated assuming all cysteines are involved in disulfide bridges. The hydrophobicity is 
presented relative to low and high hydrophobic RS. 
 
 
FcRn column retention times did not correlate with the hydrophobicity or the 
isoelectric points or the net charges of the Fv domains at lysosomal pH 6.0 or 
physiological pH 7.4. Instead it was observed that FcRn column retention times 
increased with the extent of positively charged regions on the Fv structures, 
especially around the VL domain. Figure 4-27 summarizes the pH-dependent FcRn-
mAb interaction of all mAbs and the corresponding charge distributions in the Fv 
domain. 
 
Ret.Time 
[min]
calc. pI 
(IgG)
q (VL) 
pH 6
q(VL) 
pH 7.4
q(VH) 
pH 6
q(VH) 
pH 7.4
q(Fv) 
pH 6.0
q(Fv) 
pH 7.4
Hydro-
phobicity 
[%]
Ustekinumab 84.3 1.0 9.4 2.1 1.9 3.1 2.9 5.2 4.9 -1
mAb 1 84.3 1.0 ± 0.22 9.5 2.1 1.9 3.1 2.9 5.2 4.9 -6
mAb 4 84.5 0.5 ± 0.08 9.5 2.1 1.9 6.4 4.3 8.4 6.2 -4
mAb 5 85.1 0.9 ± 0.16 9.6 2.1 1.9 4.1 3.9 6.1 5.9 13
mAb 10 85.1 1.1 ± 0.09 9.0 0.8 0.0 1.4 -0.7 2.2 -0.6 34
mAb 6 86.2 0.4 ± 0.17 9.4 3.9 3.0 5.4 3.3 9.2 6.3 12
mAb 9 86.2 0.4 ± 0.04 9.4 0.8 0.0 6.4 4.3 7.2 4.3 16
mAb 8 90.1 0.4 ± 0.07 9.3 3.8 3.0 1.4 -0.7 5.2 2.3 24
mAb 7 90.4 0.2 ± 0.03 9.4 3.8 3.0 3.4 1.3 7.2 4.3 13
mAb 3 92.4 0.2 ± 0.06 9.5 3.8 3.0 3.1 2.9 6.9 6.0 8
mAb 2 93.0 0.3 ± 0.19 9.4 3.8 3.0 6.4 4.3 10.2 7.3 8
Briakinumab 93.7 0.2 ± 0.07 9.7 3.8 3.0 6.4 4.3 10.2 7.3 7
rel. KD
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Figure 4-27: pH-dependent FcRn-mAb interaction of all mAbs 
A molecular surface representation of the structural models, protonated at pH 7.4, was 
superimposed with isopotential surfaces contoured at 2 kBT/e. A second horizontal axis 
indicates the elution pH, interpolated from offline pH measurements. Sample peaks are 
normalized to Briakinumab’s main peak. 
4.4.2.3. FcRn affinity chromatography using a salt gradient 
Based on the previous findings that the FcRn-mAb interaction seems to be charge-
mediated, a method was developed to analyze charge-mediated interactions within 
one run. For this purpose, the pH-gradient FcRn affinity chromatography method 
was modified. The FcRn column was used but a salt gradient from 0 to 250 mM 
NaCl at pH 7.8 instead of a pH-gradient was used. Antibodies with larger charged 
regions should need higher salt concentrations to dissociate from the FcRn and have 
an increased retention time. The elution order of the mAbs is nearly identical using 
pH-gradient and salt-gradient FcRn affinity chromatography (Figure 4-28). Except 
mAb 10 has a different elution profile with reduced FcRn column retention times 
using salt gradient instead of pH gradient. The peak pattern of mAb 10 has also a 
non-uniform form which indicates that the sample may include fractions with 
different FcRn binding. This phenomenon could not be elucidated, but in general 
antibodies with larger positively charged regions in the Fv domain need higher salt 
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concentrations to dissociate from the FcRn. This finding also confirms the charge-
mediated FcRn-mAb interaction. 
 
Figure 4-28: Salt-dependent FcRn-mAb interaction of all mAbs 
A molecular surface representation of the structural models, protonated at pH 7.4, was 
superimposed with isopotential surfaces contoured at 2 kBT/e. Sample peaks are normalized 
to Briakinumab’s main peak. 
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4.5. In vivo studies 
To analyze if different FcRn-mAb interactions have an influence on PK, in vivo 
studies in human FcRn transgenic and FcRn knockout mice were performed. 
4.5.1. In vivo study in human FcRn transgenic mice 
To assess whether the effect of modified charged regions in the variable domains on 
FcRn-mAb interaction translates into modulated in vivo PK properties, PK studies in 
human FcRn transgenic mice were conducted. Briakinumab, Ustekinumab, together 
with Briakinumab-variants with modified charge distribution in the VH (mAb 8) and 
VL domain (mAb 9), were tested. These four antibodies were chosen because the 
elution pHs were equally distributed between pH 7.4 and 7.9 (Figure 4-29). 
Additionally, mAb 8 and mAb 9 are Briakinumab-variants with modified charge 
distribution in the VH and VL domain, respectively, therefore the effect of different 
charge distributions in the Fv domain on PK can be investigated. 
 
Figure 4-29: FcRn column chromatogram of antibodies used in mouse PK 
study 
Ustekinumab, mAb 9, mAb 8 and Briakinumab have elution pHs of 7.4, 7.5, 7.7 and 7.9, 
respectively. Sample peaks are normalized to Briakinumab’s main peak. 
After i.v. administration of 10 mg/kg antibody, the typical kinetic profile for an IgG1 
was observed (Figure 4-30), which is divided into alpha and beta phases (Roopenian 
et al. 2010). The alpha phase occurs rapidly (in the first 24 hours) and shows mainly 
the distribution process until the administered antibody reaches equilibrium. The beta 
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phase demonstrates the log-linear serum concentration-time relationship in the 
following days where elimination processes occur. The kinetic profiles show that 
Briakinumab has a different alpha phase with faster distribution compared to the 
alpha phases of Ustekinumab, mAb 8 and mAb 9. Ustekinumab, mAb 8 and mAb 9 
are comparable within the first 24 hours.  
 
Figure 4-30: Blood level curves in human FcRn transgenic mice 
Antibodies were administered as a single i.v. bolus injection of 10 mg/kg to 6 animals per 
group. Data points represent the mean ± standard deviation.  
The following PK parameters were calculated and summarized in Table 4-11: area 
under the curve (AUC0-inf), clearance (Cl), volume of distribution at steady state 
(VSS) and the terminal half-life (T1/2).  
Table 4-11: PK parameters in human FcRn transgenic mice 
PK parameters were calculated after administration of 10 mg/kg to 6 animals per group. PK 
data represent the mean ± standard deviation.  
Sample 
AUC0-inf 
[h*mg/mL] 
Cl 
[mL/min/kg] 
VSS 
[L/kg] 
T½ 
[h] 
Briakinumab 4.3 ± 0.2 0.0394 ± 0.001 0.162 ± 0.015 48 ± 9 
Ustekinumab 12.2 ± 0.9 0.0137 ± 0.001 0.116 ± 0.006 137 ± 48 
mAb 8 11.5 ± 0.8 0.0146 ± 0.001 0.101 ± 0.013 78 ± 22 
mAb 9 16.0 ± 0.9 0.0104 ± 0.001 0.099 ± 0.011 109 ± 13 
 
AUC0-inf and clearance are influenced by distribution and elimination processes. Due 
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to Briakinumab’s different alpha phase AUC0-inf and Cl differ between Briakinumab 
and the other mAbs. Briakinumab has also a bigger VSS than the other mAbs.  
The focus of this work was to elucidate the influence of the Fv domain on FcRn-
mediated IgG-recycling, therefore the terminal half-life was examined, which is 
exclusively calculated in the elimination phase where FcRn-mediated IgG-recycling 
dominates (Roopenian et al. 2010). The order by T1/2 is the following: 
Briakinumab < mAb 8< mAb 9 < Ustekinumab. 
The terminal half-lives were compared with the isoelectric points and the 
hydrophobicity of the mAbs. Neither isoelectric points nor the hydrophobicity 
correlate with the terminal half-life in vivo (Figure 4-31) indicating that these 
parameters do not mainly influence the terminal half-life. In contrast, the terminal 
half-lives of the four antibodies correlate linearly with the in vitro FcRn column 
elution pHs (Figure 4-32). Higher FcRn column elution pHs result in shorter terminal 
half-lives. A Pearson correlation factor of 0.9924 confirms an existing correlation 
between terminal half-life in vivo and FcRn column elution pH in vitro. 
 
Figure 4-31: Correlation between terminal half-life and isoelectric point or 
hydrophobicity 
Terminal half-lives are plotted against (a) isoelectric points and (b) hydrophobicity. 
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Figure 4-32: Correlation between in vivo terminal half-life and FcRn column 
elution pH 
Terminal half-lives are plotted against the corresponding elution pHs. A regression line is 
generated and the correlation factor R
2
 is calculated. 
A statistical analysis of the terminal half-lives was calculated using the Tukey HSD 
Test. A statistically significant difference could be detected between the terminal 
half-lives of Briakinumab and Ustekinumab, Briakinumab and mAb 9 as well as 
Ustekinumab and mAb 8.  
PK can also be influenced by anti-drug antibodies (ADAs), therefore serum samples 
were tested for the existence of ADAs by detection of drug/ADA immune 
complexes. After i.v. administration of 10 mg/kg Briakinumab in human FcRn 
transgenic mice Briakinumab/ADA immune complexes were first detected after 
about 336 hours (14 days, Table 4-12). 
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Table 4-12: ADA-positive samples after Briakinumab administration in 
human FcRn transgenic mice 
Serum concentrations of each sampling time point after i.v. administration of 10 mg/kg 
Briakinumab. ADA-positive samples are illustrated as * and ** describing formation of 
moderate and severe drug/ADA immune complexes, respectively. (B.l.q. =  below  limit of 
quantification) 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
0.08 201 174 188 192 214 194 
2 109 105 106 105 110 110 
8 50 53 53 54 56 58 
24/ 1 37 32 30 34 35 35 
48/ 2 27 23 24 27 24 28 
168/ 7 6.2 5.4 6.7 6.7 * 6.4 6.8 
336/ 14 0.4 1.0 * 0.1 ** 0.2 ** 0.7 * 0.1** 
504/ 21 b.l.q. b.l.q.** b.l.q.** b.l.q.** b.l.q.** b.l.q.** 
672/ 28 b.l.q. b.l.q.** b.l.q. b.l.q.** b.l.q.** b.l.q.** 
 
After administration of mAb 8 and mAb 9 drug/ADA immune complexes were also 
detected after about 336 hours (14 days, Table 7-3 and Table 7-4). The 
concentration-time curves show no rapid decrease due to ADA formation, therefore 
the influence on PK is assessed to be neglected. 
In contrast, administration of Ustekinumab did not cause formation of 
Ustekinumab/ADA immune complexes in human FcRn transgenic mice (Table 7-2). 
4.5.2. In vivo study in FcRn knockout mice 
To confirm that differences in the terminal half-lives in human FcRn transgenic mice 
were caused by different FcRn-mAb interactions, a second in vivo study in FcRn 
knockout mice was conducted. In order to reduce the number of mice used in this 
study, only three antibodies were used: Briakinumab, Ustekinumab and mAb 9. 
After i.v. administration of 10 mg/kg antibody the clearance of all antibodies is much 
faster in FcRn knockout mice than in human FcRn transgenic mice due to missing 
FcRn-mediated IgG-recycling. Division in alpha and beta phase is not clearly 
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definable because antibodies are eliminated very fast. It can be demonstrated that 
Briakinumab has a different pharmacokinetic behavior with faster distribution in the 
first hours after administration compared to Ustekinumab and mAb 9 (Figure 4-33). 
These findings were also observed in human FcRn transgenic mice indicating that 
the distribution process in the first hours after administration is not FcRn-mediated.  
 
Figure 4-33: Blood level curves in FcRn knockout mice 
Antibodies were administered as a single i.v. bolus injection of 10 mg/kg to 6 animals per 
group. Data points represent the mean ± standard deviation. 
The following PK parameters were calculated and summarized Table 4-13: AUC0-inf, 
Cl, VSS and T1/2. 
Table 4-13: PK parameters in FcRn knockout mice 
PK parameters were calculated after administration of 10 mg/kg to 6 animals per group. PK 
data represent the mean ± standard deviation.  
Sample 
AUC0-inf 
[h*mg/mL] 
Cl 
[mL/min/kg] 
VSS 
[L/kg] 
T½ 
[h] 
Briakinumab 1.0 ± 0.1 0.163 ± 0.008 0.113 ± 0.004 10.6 ± 0.6 
Ustekinumab 3.3 ± 0.1 0.051 ± 0.002 0.077 ± 0.004 22.8 ± 1.1 
mAb 9 2.9 ± 0.1 0.059 ± 0.003 0.093 ± 0.005 23.2 ± 1.2 
 
Ustekinumab and mAb 9 are comparable regarding AUC0-inf, Cl, VSS and T1/2. 
Briakinumab has a smaller AUC0-inf, faster Cl and smaller T1/2 than Ustekinumab and 
mAb 9. The calculation of T1/2 might differ from the actual value, because time 
points after 3 and 4 days would have been needed to calculate T1/2  more precisely. 
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The statistical analysis of the terminal half-lives was calculated using the Tukey 
HSD Test. A statistical significance could be detected between the terminal half-lives 
of Briakinumab and Ustekinumab and of Briakinumab and mAb 9.  
The formation of ADAs was tested by detection of drug/ADA immune complexes. In 
FcRn knockout mice administration of 10 mg/kg Briakinumab resulted in formation 
of Briakinumab/ADA immune complexes after about 168-192 hours (7-8 days, Table 
4-14).  
Table 4-14: ADA-positive samples after Briakinumab administration in FcRn 
knockout mice 
Serum concentrations of each sampling time point after i.v. administration of 10 mg/kg 
Briakinumab in FcRn knockout mice. ADA-positive samples are illustrated as * and ** 
describing formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
0.08 192 181 200 187 186 178 
2 86 79 74 91 89 91 
8 31 32 36 31 29 33 
24/ 1 6.7 12 7.9 11 6.9 8.0 
48/ 2 1.8 2.3 2.7 2.6 2.4 2.2 
168/ 7 b.l.q. b.l.q. b.l.q. ** b.l.q. b.l.q. ** b.l.q. 
192/ 8 b.l.q. * b.l.q. * b.l.q. ** b.l.q. * b.l.q. ** b.l.q. ** 
216/ 9 b.l.q. * b.l.q. b.l.q. ** b.l.q. ** b.l.q. * b.l.q. ** 
336/ 14 b.l.q. b.l.q. ** b.l.q. * b.l.q. ** b.l.q. ** b.l.q. * 
 
After administration of mAb 9, drug/ADA immune complexes were also first 
detected after about 168 hours (7 days, Table 7-7). After administration of 
Ustekinumab, no Ustekinumab/ADA complexes were detected in FcRn knockout 
mice (Table 7-6). The concentration-time curves of Briakinumab and mAb 9 show 
no rapid decrease due to ADA formation. Ustekinumab and mAb 9 have very similar 
concentration-time curves indicating that ADA formation after mAb 9 administration 
does not influence PK.  
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4.6. Second model antibody 
The transferability of the results from the Briakinumab-Ustekinumab model 
antibodies was tested using a second antibody: Bevacizumab. 
A Bevacizumab-variant was produced with three amino acids in the CDRs mutated 
to lysines in the VL domain to generate a variant with additional positively charged 
regions. Figure 4-34 presents the sequence alignment of the light chains. 
 
 
Figure 4-34: LC-alignment of Bevacizumab and Bevacizumab-variant 
Identical amino acids are shown in cyan; VL domains are shown in italics; CDRs are marked 
with an asterisk (*).  
The heavy chains are identical for Bevacizumab and Bevacizumab-variant (Table 
4-15). 
 
 
 
            ******* ****         * ****** 
Bevacizumab          DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPS  
Bevacizumab-variant  DIQMTQSPSS LSASVGDRVT ITCSASQKIS NYLNWYQQKP GKAPKVLIYF TSSKHSGVPS  
 
        ** ******* 
Bevacizumab          RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKRTV AAPSVFIFPP  
Bevacizumab-variant  RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSKVPWTFGQ GTKVEIKRTV AAPSVFIFPP  
 
 
Bevacizumab          SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT  
Bevacizumab-variant  SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT  
 
 
Bevacizumab          LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEEVQLVES GGGLVQPGGS LRLSCAASGY  
Bevacizumab-variant  LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEEVQLVES GGGLVQPGGS LRLSCAASGY  
 
 
Bevacizumab          TFTNYGMNWV RQAPGKGLEW VGWINTYTGE PTYAADFKRR FTFSLDTSKS TAYLQMNSLR  
Bevacizumab-variant  TFTNYGMNWV RQAPGKGLEW VGWINTYTGE PTYAADFKRR FTFSLDTSKS TAYLQMNSLR  
 
 
Bevacizumab          AEDTAVYYCA KYPHYYGSSH WYFDVWGQGT LVTVSSASTK GPSVFPLAPS GTAALGCLVK  
Bevacizumab-variant  AEDTAVYYCA KYPHYYGSSH WYFDVWGQGT LVTVSSASTK GPSVFPLAPS GTAALGCLVK  
 
 
Bevacizumab          DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS  
Bevacizumab-variant  DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS  
 
 
Bevacizumab          NTKVDKKVEP K  
Bevacizumab-variant  NTKVDKKVEP K  
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Table 4-15: Bevacizumab and Bevacizumab-variant with additional positively 
charged regions in the VL domain 
Mutation of three amino acids in the CDRs to lysines is illustrated as 1 blue dot. An asterisk 
(*) marks mutated amino acid residues according to the EU numbering of Kabat. 
Name Description 
 
Bevacizumab Bevacizumab wild type 
 
Bevacizumab-
variant 
Bevacizumab  D27
LC
K, L54
LC
K, T93
LC
K* 
 
 
4.6.1. Biochemical characterization 
The biochemical characterization included measurement of protein concentration, 
size and MW distribution. The results are summarized in Table 4-16.  
Table 4-16: Overview biochemical characterization of Bevacizumab and 
Bevacizumab-variant 
The concentration is given as the average of 3 measurements. Monomer contents are 
determined by integration of the SEC-chromatogram. Purity of antibody species is 
determined by CE-SDS of the intact mAbs and after DTT-reduction. 
Sample Conc. 
[mg/mL] 
SEC       
[%] 
CE-SDS [%] 
Intact mAb HC LC 
Bevacizumab 2.40 99.7 93 70 30 
Bevacizumab-
variant 
2.10 99.6 97 69 31 
 
Bevacizumab and Bevacizumab-variant show high monomer contents of at least 
99%. The intact mAbs, cleaved HCs and LCs show MWs of about 156-161, 60 and 
26-27 kDa, respectively (Figure 4-35). The purity of the intact mAbs and chains is 
very high (Table 4-16). 
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Figure 4-35: Molecular weight of Bevacizumab and Bevacizumab-variant and 
DTT-reduced mAbs 
Gel-like images of the intact mAbs and after DTT-reduction into HCs and LCs. 
4.6.1.1. Charge distribution analysis 
The charge distribution of Bevacizumab revealed no striking positively or negatively 
charged regions in the Fv domain. By mutation of two neutral (L54, T93) and one 
acidic amino acid residue (D27) to basic lysines, a larger positively charged region in 
the VL domain was created (Figure 4-36).  
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Figure 4-36: Charge distribution of Bevacizumab and Bevacizumab-variant 
Isopotential surfaces of the proteins protonated at pH 7.4 and contoured at 1 kBT/e; blue: 
positive; red: negative. A different contour level (1 kBT/e instead of 2 kBT/e) is used for 
clarity. Orange oval highlights the region of increased positive charge. The light and heavy 
chains are shown in light and dark grey, respectively. The view focuses on the CDRs.  
4.6.2. Functional characterization 
The functional characterization consisted of a target binding ELISA. 
The Bevacizumab and the Bevacizumab-variant with additional positively charged 
residues in the Fv domain both bind to VEGF. The binding of the Bevacizumab-
variant is slightly reduced to 90% which ranges in the assay deviation (Figure 4-37). 
 
Figure 4-37: VEGF binding of Bevacizumab and Bevacizumab-variant 
The absorbance-concentration curves of Bevacizumab and Bevacizumab-variant are similar 
indicating comparable VEGF affinities.  
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4.6.3. FcRn-mAb dissociation  
Bevacizumab and Bevacizumab-variant showed FcRn column retention time 
differences of 2.2 min (Figure 4-38). Bevacizumab eluted at an elution pH of 7.4 and 
Bevacizumab-variant at pH 7.6. The higher elution pH of the Bevacizumab-variant 
confirms that additional positively charged regions in the Fv domain result in mAb-
FcRn dissociation at higher pH values. 
 
Figure 4-38: FcRn column chromatogram of Bevacizumab and Bevacizumab-
variant 
Sample peaks are normalized to Bevacizumab’s main peak. 
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5. Discussion 
The discussion addresses the question if the Fab region influences FcRn-dependent 
PK. Briakinumab and Ustekinumab are a very good model system to investigate the 
influence of the Fab region on PK, because both antibodies have nearly identical Fc 
sequences and the same target specificity but different terminal half-lives in humans 
(Gandhi et al. 2010). To investigate the reasons for different PK profiles, factors 
influencing PK, like target affinity, presence of aggregates and isoelectric points, are 
analyzed and discussed. Another approach is to study if differences in PK can occur 
due to differences in the interaction with FcRn. To better understand the influence of 
the Fab region on PK, systematically engineered variants of Briakinumab and 
Ustekinumab with cross-over exchanges and modified charge distribution in the Fab 
region are produced to localize the influencing structural element of the Fab region 
and to analyze if the interaction is charge-mediated. Finally, the transferability of the 
findings to other antibodies is discussed. 
Biochemical characterization 
111 
 
5.1. Biochemical characterization 
The aim of the biochemical characterization was to find differences between 
Briakinumab and Ustekinumab that might explain the reported differences in the PK 
behavior in humans (Lima et al. 2009; Zhu et al. 2009).  
First, antibodies were tested for their tendency to form aggregates, because the 
formation of protein aggregates can effect PK in a direct way due to FcɣR 
interactions or indirectly via immunogenic reactions (Putnam et al. 2010). IgG 
dimers were found to activate immune cells (macrophages and neutrophils) through 
FcɣR triggering (Bleeker et al. 2001). This can result in a higher rate of phagocytosis 
and increased clearance. High aggregate contents are also reported to induce 
immunogenic reactions (Putnam et al. 2010). Protein aggregates have a high 
molecular weight, contain repetitive epitopes and can therefore mimic viruses or 
bacteria. By binding and cross-linking of B-cell receptors, the formation of ADAs is 
induced. Formation of drug/ADA immune complexes can subsequently induce a 
quick elimination of the drug (Brinks et al. 2011). The focus of this work was on 
soluble aggregates which were analyzed by SEC. In future experiments it would also 
be interesting to study aggregate formation in more detail, e.g. by analysis of 
subvisible protein particles. SEC chromatograms of Briakinumab and Ustekinumab 
show that the content of soluble aggregates is low (< 3%) with the majority of MWs 
being dimers (Figure 4-3). Furthermore both antibodies are resistant to freeze-thaw 
and storage-temperature stress. There was hardly any aggregate formation in the 
stressed samples (Table 4-3 and Table 4-4), so the tendency to form aggregates is for 
both antibodies relative low. In conclusion, differences in PK are probably not 
influenced by the presence of soluble aggregates.  
Second, the question was raised if differences in hydrophobicity cause differences in 
PK. Hydrophobicity is defined as the tendency to repel water (Chandler 2005). The 
antibody structure is folded so that hydrophobic amino acids are clustered together 
and form a hydrophobic core within the protein. A high content of hydrophobic 
amino acid residues on the protein surface can be one factor for increased tendency 
of protein aggregation (Haverick et al. 2014; Joubert et al. 2011). Measured by HIC, 
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Briakinumab is slightly more hydrophobic than Ustekinumab, but compared to high 
and low hydrophobic reference samples they are both in a low hydrophobic range 
(Figure 4-4).  
Third, differences in the isoelectric point (pI) were discussed as reason for PK 
differences. The isoelectric point describes the pH at which antibodies carry no 
electrical net charge (Boswell et al. 2010). Previous studies have discussed pI 
differences to be a driving force for altered PK by affecting the electrostatic 
interaction between the antibody and negatively charged groups on the surface of 
endothelial cells (Khawli et al. 2002; Khawli et al. 2010; Putnam et al. 2010). For 
example, Igawa et al. (2010) observed that IgG4 antibodies with lower isoelectric 
points due to engineering in the variable region have a lower rate of fluid-phase 
pinocytosis and in turn a reduced elimination rate. Here, Ustekinumab has a lower 
isoelectric point and longer terminal half-life than Briakinumab which could be due 
to a lower rate of fluid-phase pinocytosis. On the other hand, mAb 8, having a lower 
pI  than Ustekinumab and mAb 9, has a shorter terminal half-life which differs from 
Igawa’s et al. (2010) observation. Furthermore, Boswell et al. (2010) proposed the pI 
differences needed to be at least of one unit to influence PK. In contrast, the pIs of 
Briakinumab and Ustekinumab vary between 9.4 and 9.7 (Table 4-5). Therefore, the 
influence on fluid-phase pinocytosis is assumed to be minimal.  
Finally, the charge distribution was analyzed to look for striking positively or 
negatively charged regions. Isopotential surfaces were calculated from the crystal 
structure (Ustekinumab) or homology models (Briakinumab and all variants) and 
illustrate a modeled charge distribution. The calculated size of the charged regions at 
pH 7.4 does not correlate with the net charge of the VH, VL or Fv domain at pH 7.4 
(Table 4-10). Position and size of the charged regions can therefore only be visual 
rated and not be classified by a specific value. It was observed that Briakinumab has 
a large positively charged region in the Fab which is absent in Ustekinumab. The 
location of the positively charged region spreads across the VH and the VL domains 
(Figure 4-5). The variants of Briakinumab and Ustekinumab have also differences in 
the charge distribution due to cross-over exchanges and mutations in the Fv domain. 
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On the other hand, FcRn possesses an extended negatively charged region (Figure 
4-7) which is not involved in cognate Fc binding.  
Thus, the hypothesis was proposed that positively charged regions in the Fv domain 
interact with negatively charged regions on the FcRn, thereby strengthening the 
FcRn-IgG interaction at physiological pH which in turn leads to less efficient IgG-
recycling and shortened terminal half-lives in vivo. 
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5.2. Functional characterization 
A functional characterization was performed to test if antibodies have different 
affinities to IL-12 an IL-23 of different species and to mouse FcɣRI. Analysis of the 
interaction with the target (human IL-12) was performed to test if target binding is 
still functional, although antibody variants were modified in the Fab region. The 
cross-reactivity of the antibodies to mouse IL-12/-23 was analyzed to exclude target-
mediated clearance effects in a mouse PK study. In addition, binding to mouse Fcɣ 
receptor I (muFcɣRI) was measured because stronger binding to mouse FcɣRI could 
lead to a faster decrease of serum concentrations in a PK study due to faster uptake 
into antigen-presenting cells. 
The affinity to human IL-12 was tested to confirm that functional active antibodies 
were produced. Briakinumab, Ustekinumab and mAbs with exchanged Fv domains 
(mAb 1 and 2) have nearly identical affinities to IL-12. In contrast, exchange of the 
LCs (mAb 3 and 4) and of the CDRs (mAb 5 and 6) results -as expected- in complete 
functional loss (Figure 4-10). Binding of Briakinumab and Ustekinumab to IL-12 is 
based on van der Waals forces and mainly on electrostatic interactions (Luo et al. 
2010). Amino acid residues of the LCs and HCs form the CDRs. Both HC-CDRs and 
LC-CDRs are involved in the paratope and are therefore essential for target binding. 
The four variants with modified charge distributions in the Fv domain (mAb 7-10) 
still bind to IL-12, although the IL-12 affinity compared to Briakinumab is reduced 
(Figure 4-11). Therefore, it can be demonstrated that altering the charge distribution 
in the Fv domain of Briakinumab does not result in complete functional loss and that 
study samples of mAb 8 and mAb 9 can be analyzed using the target-specific ELISA.  
Furthermore it was tested whether Briakinumab, Ustekinumab, mAb 8 and mAb 9 
(mAbs used in the in vivo study) bind to mouse IL-12 and IL-23, because in the 
mouse study only target-independent clearance effects were addressed. It was 
reported that Briakinumab and Ustekinumab are not cross-reactive to mouse IL-12 
(Luo et al. 2010; Traczewski and Rudnicka 2012); Ustekinumab does not bind mouse 
IL-12 because the murine p40-subunit differs in three amino acid residue clusters and 
especially one cluster (mouse: 40LDQSSEVL47 vs. human: 40SDQRHGVI47) is 
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essential for Ustekinumab binding (Luo et al. 2010). None of the four mAbs binds to 
mouse IL-12 and mouse IL-23, therefore target-dependent clearance effects can be 
excluded (Figure 4-13).  
The binding to mouse FcɣRI was analyzed because stronger binding to mouse FcɣRI 
could lead to a faster decrease of serum concentrations in a PK study due to faster 
uptake of the antibody into antigen-presenting cells, followed by faster elimination in 
the alpha phase (Bleeker et al. 2001). Briakinumab and Ustekinumab show different 
binding levels to mouse FcɣRI (Figure 4-14) suggesting that the Fab region could 
also influence the mouse FcɣRI-IgG interaction. Therefore, Briakinumab’s stronger 
binding to mouse FcɣRI could result in a faster elimination in the first hours after 
administration due to a faster uptake into antigen-presenting cells and a faster 
elimination. The binding site of FcɣRI is located at the lower hinge region of IgG 
(Burton and Woof 1992; Duncan et al. 1988) and the interaction between FcɣRI and 
IgG is reported to be mainly influenced by the glycosylation of the Fc region 
(Jefferis 2009). The Fab region has not been described to influence the interaction 
with FcɣRI, but it would be interesting to further study this interaction with more 
appropriate tools to get stronger data. Here, only binding levels were compared 
which is not sufficient for an accurate statement. In the beta phase FcRn-mediated 
recycling dominates, especially in human FcRn transgenic mice (Roopenian et al. 
2010), therefore the influence of the mouse FcɣRI-mAb interaction should be 
minimal in the beta phase. 
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5.3. FcRn-mAb interaction 
The biochemical characterization of all antibodies showed no striking differences 
between Briakinumab, Ustekinumab and the variants, therefore the FcRn-mAb 
interaction was studied next to elucidate the contribution of the FcRn-IgG interaction 
on PK. The prolonged terminal half-life of IgG1 is predominantly mediated by the 
interaction with the FcRn (Ghetie and Ward 2000) which is strictly pH-dependent 
showing high affinity at pH 6.0 and negligible binding at pH 7.4 (Goebl et al. 2008; 
Ober et al. 2004b). This strict, pH-dependent bind-and-release mechanism is critical 
for IgG-recycling and any deviation of the binding characteristics at different pHs 
may strongly influence circulation half-lives of IgGs (Vaccaro et al. 2005). 
Therefore, the FcRn-mAb interaction was analyzed in two separate parts; the affinity 
at pH 6.0 and the dissociation at higher pH values.  
At first the FcRn-mAb affinity at pH 6.0 was analyzed. The equilibrium dissociation 
constant KD fell in a narrow range for all mAbs (Table 4-8) and the slight differences 
are considered to be negligible. It was reported that increased pH 6.0 binding can 
result in prolonged terminal half-lives (Suzuki et al. 2010). Briakinumab showed a 
slightly higher FcRn affinity at pH 6.0, although the terminal half-life of 
Briakinumab is shorter than of Ustekinumab, indicating that differences in PK are 
not caused by different FcRn affinities at pH 6.0. 
Due to Briakinumab’s and Ustekinumab’s similar pH 6.0 affinities to FcRn, the 
second step was to analyze the pH-dependent FcRn-mAb dissociation. Using SPR 
and FcRn affinity chromatography, it was shown that the dissociation of the 
Briakinumab-FcRn complex is very different from the dissociation of the 
Ustekinumab-FcRn complex. Briakinumab and Ustekinumab showed striking 
retention time differences (Figure 4-16). Ustekinumab eluted at an elution pH of 7.4, 
whereas Briakinumab eluted at pH 7.9. These differences in FcRn-mAb dissociation 
were suspected to be a reason for the different terminal half-lives in vivo (Gandhi et 
al. 2010). Yeung et al. (2009) have described that efficient pH-dependent release of 
IgGs at pH 7.4 is essential for engineering antibodies with increased terminal half-
lives. Briakinumab is released at higher pH values and therefore the dissociation at 
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the cell surface could be too slow resulting in only partial Briakinumab recycling to 
the systemic circulation. The hypothesis is that Briakinumab is transported back into 
the cell and finally being degraded after all. In contrast, Ustekinumab is released 
from the FcRn at physiological pH of 7.4 at the cell surface and is recycled back to 
the systemic circulation resulting in a prolonged terminal half-life. 
In order to find the structural region that is responsible for different FcRn column 
retention times, the cleaved Fc fragments of Briakinumab and Ustekinumab were 
tested for FcRn-Fc dissociation. The F(ab’)2 region alone showed only very weak 
affinity to FcRn at pH 5.5 indicating that for the interaction with FcRn the Fc region 
is indispensable. Therefore modifications in the Fc region are reported to mainly 
influence FcRn-IgG binding and the Fab region to influence FcRn-IgG dissociation 
(Dall'Acqua et al. 2006; Petkova et al. 2006; Schlothauer et al. 2013). The nearly 
identical FcRn column retention times of the cleaved Fc fragments of Briakinumab 
and Ustekinumab (Figure 4-17) confirmed that the minor differences in the amino 
acid sequence of the Fc region do not influence FcRn-mAb dissociation. In 
conclusion, the Fab region has to be responsible for differences in FcRn column 
retention times of Briakinumab and Ustekinumab. The influence of the Fab region on 
FcRn interactions has recently been discussed (Schlothauer et al. 2013; Suzuki et al. 
2010; Wang et al. 2011). Schlothauer et al. (2013) showed that IgGs with identical 
Fc regions differ in their dissociation from FcRn in vitro and Wang et al. (2011) 
indicated that IgGs with excessive binding to FcRn at pH 7.3 suffer from reduced 
terminal half-lives. However, it remained unknown which exact structural parts of 
the Fab region influence FcRn-mAb interaction and the underlying mechanism of 
this interaction.  
The FcRn interaction of antibody variants with cross-over exchanges between 
Briakinumab and Ustekinumab was analyzed to obtain information on structural 
parts that mainly influence FcRn-IgG interaction. The analysis of this interaction 
revealed that mAbs with identical Fv domains and LCs elute at nearly identical FcRn 
column retention times (Figure 4-18 and Figure 4-19). Grafting Ustekinumab CDRs 
on Briakinumab shifts the retention times close to that of Ustekinumab. The other 
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way around, grafting Briakinumab CDRs on Ustekinumab presented an elution 
profile which was still close to Ustekinumab (Figure 4-20). The reason for this 
phenomenon could not be fully elucidated, but it was assumed that the FcRn 
interaction is affected by the different charge distribution in the Fv domain of 
Briakinumab and Ustekinumab. Briakinumab shows a large positively charged 
region on the Fv domain which is absent in Ustekinumab. Therefore the FcRn-mAb 
interaction is probably more affected by disrupting the large positively charged 
region of Briakinumab in the Fv domain than by creating a positively charged region 
which was significantly smaller. Combining the results of the structural analysis of 
the FcRn-mAb interaction leads to the conclusion that the Fv domain and especially 
the light chain variable domain (VL) provides the main influence on the FcRn-mAb 
dissociation. This finding was unexpected because the Fv domain is distant from the 
cognate FcRn-binding site. 
The extended positively charged regions in the Fv domain of Briakinumab lead to the 
hypothesis that the FcRn-mAb interaction is charge-mediated. To test this 
hypothesis, Briakinumab variants with smaller positively charged regions were 
analyzed for FcRn-mAb dissociation. Smaller positively charged regions located in 
the VH domain resulted in a retention time shift in the direction of Ustekinumab 
(Figure 4-25). The retention time shift was not as pronounced as with exchanged LCs 
or Fv domains, but they nevertheless influence FcRn column dissociation. Smaller 
positively charged regions located in the VL domain resulted in a big retention time 
shift in the direction of Ustekinumab (Figure 4-26) indicating that the major 
influence on FcRn-mAb interaction is specific located charge in the Fv domain.  
To test this observation, FcRn column retention times of all antibodies were 
compared with the FcRn affinity at pH 6.0, hydrophobicity, isoelectric points, net 
charges of the Fv domains at pH 6.0 and pH 7.4 and with the extent of charged 
regions in the Fv structures (Table 4-10). Engineering antibodies to increase pH 6.0 
binding to FcRn has been reported to simultaneously increase binding at pH 7.4 
(Suzuki et al. 2010). In this study, differences in pH 6.0 affinity are too small to 
affect FcRn-mAb dissociation. Hydrophobicity could also affect FcRn-mAb 
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dissociation, because a high content of hydrophobic residues on the protein surface 
can increase the tendency of aggregation to minimize hydrophobic surfaces (Joubert 
et al. 2011). Therefore the dissociation tendency between FcRn and antibody could 
be reduced to cover hydrophobic antibody surfaces, but all mAbs are low 
hydrophobic and the FcRn retention times do not correlate with hydrophobicity. The 
isoelectric point is a parameter that describes the net charge of the whole antibody. 
The pI values range between 9.0 and 9.7 and do not correlate with FcRn column 
retention times indicating that the whole antibody net charge does not influence 
FcRn-mAb dissociation in this experiment. Furthermore there is no correlation 
between the net charges of the Fv domains at pH 6.0 and FcRn column retention 
times, because retention times describe the FcRn-mAb dissociation which occurs at 
higher pH values (Raghavan and Bjorkman 1996). Neither, do the net charges of the 
Fv domains at pH 7.4 seem to mainly influence FcRn-mAb dissociation. However, a 
closer look into FcRn column dissociations of all antibodies reveals that FcRn 
column retention times increased with the extent of positively charged regions on the 
Fv domains (Figure 4-27), especially around the light chain variable domains.  
These findings demonstrate that specific charged regions in the Fv domain strongly 
influence FcRn-mAb dissociation. It was assumed that positively charged regions in 
the Fv domain could interact with negatively charged regions on FcRn. However, it 
remained unknown how the distal Fv domain interacts with the FcRn. To elucidate 
this interaction, Dr. Hubert Kettenberger (Biochemical & Analyticals Research, 
Roche Diagnostics GmbH, Mannheim, Germany, Site Penzberg) studied molecular 
dynamics simulations of the FcRn-mAb complexes. (The following findings were 
described by personal communication and are presented in the publication, “Charge-
mediated Influence of the Antibody Variable Domain on FcRn-Dependent 
Pharmacokinetics”, which is currently under revision). Briefly, the dynamics of the 
FcRn-IgG complexes were studied over a period of 100 ns in explicit water and 
physiological ionic strength. During the course of the simulation, one of the two Fab 
regions approaches the tip of FcRn and persists in this conformation for the rest of 
the simulation time. The results of the simulation suggest that the conformational 
flexibility of the Fab arms allows them to readily assume conformations which can 
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stably interact with FcRn. The region on FcRn found to interact with the Fv domain 
has not been described before as being involved in IgG binding. Surprisingly, in the 
MD simulations not only Briakinumab but also Ustekinumab assumed a 
conformation with Fv domain and FcRn interacting with one another. However, the 
electrostatic contribution to the FcRn-Fv interaction was found to be about twice as 
high in Briakinumab as in Ustekinumab. In summary, the intrinsic flexibility of Fab 
arms in the FcRn-IgG complexes structurally allows a direct, stabilizing interaction 
of the Fv domain with the tip of FcRn.  
The charge-mediated FcRn-mAb interaction was further confirmed by analyzing the 
dissociation under high ionic strength conditions. Briakinumab’s shortened retention 
time under high ionic strength conditions indicates that the FcRn-Briakinumab 
interaction is charge-mediated (Figure 4-23). In addition, the FcRn affinity 
chromatography method was modified to analyze charge-mediated interactions 
within one run. For this purpose, a salt gradient was used instead of a pH-gradient. 
Antibodies that interact in a charge-mediated manner with the FcRn need higher salt 
concentrations to dissociate from the FcRn. The elution order of the mAbs was 
nearly the same using pH-gradient and salt-gradient FcRn affinity chromatography. 
This finding further confirms the charge-mediated nature of the FcRn-mAb 
interaction. The FcRn affinity chromatography using salt gradient elution presents a 
novel method to demonstrate differences in FcRn-mAb interaction caused by 
different charge distributions in the Fv domain.  
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5.4. In vivo studies 
The in vivo studies are necessary to test if different FcRn-mAb dissociations affect 
pharmacokinetics. Pharmacokinetics describes the concentration-time process of the 
drug from application until elimination (Benet 1984).  
To study the effect of different FcRn column dissociations, human FcRn transgenic 
mice were used because of the species-specific FcRn-IgG interaction (Roopenian et 
al. 2010). Murine FcRn binds IgG of several species, e.g. human, mouse, rabbit, 
guinea pig, bovine, sheep and rat IgG (Ober et al. 2001). On the contrary, human 
FcRn only binds human, rabbit and guinea pig IgG but not mouse IgG (Vaccaro et al. 
2006; Zhou et al. 2005). Furthermore conventional mouse model systems do not 
reliable describe the pharmacokinetics of human antibodies, because these antibodies 
have an abnormally high affinity for mouse FcRn, resulting in an artificially 
prolonged serum persistence (Ober et al. 2001; Petkova et al. 2006; Ternant and 
Paintaud 2005). 
After i.v. administration of 10 mg/kg antibody, the typical kinetic profile for an IgG1 
can be seen (Figure 4-30), which is divided into alpha and beta phase (Roopenian et 
al. 2010). The division in alpha and beta phase is typical for IgGs if target-mediated 
drug disposition (TMDD) and immunogenicity can be excluded (Ghetie and Ward 
2002). The profile of TMDD–mediated PK is non-linear and shows more than two 
phases (Mager 2006). TMDD can only occur if the human target is cross-reactive to 
the test animals target which occurs often in non-human primates and seldom in 
rodents (Mahmood and Green 2005; Mould and Green 2010). TMDD often results in 
increased clearance and is therefore also called target-mediated clearance (Gibiansky 
and Gibiansky 2009). The antibodies used in this study are not cross-reactive to the 
mouse target therefore target-mediated clearance effects can be excluded. In this 
study, the alpha phase occurs rapidly (in the first 24 hours) and shows mainly the 
distribution process until the administered antibody reaches equilibrium. 
The kinetic profiles show that Briakinumab has a different alpha phase with faster 
distribution compared to the alpha phases of Ustekinumab, mAb 8 and mAb 9. This 
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fast serum concentration decrease in the first hours after administration of 
Briakinumab could be due to a higher affinity to mouse FcɣRI (4.3.3) which could 
lead to a faster clearance. Ustekinumab, mAb 8 and mAb 9 are comparable within 
the first 24 hours.  
A detailed characterization of absorption, distribution and elimination processes is 
achieved by PK parameters.  
The distribution of mAbs is influenced by the rate of extravasation in tissue, the rate 
of distribution within tissue, the rate and extent of antibody binding in tissue, and the 
rates of elimination from tissue (Wang et al. 2008). The volume of distribution (Vd), 
also called the apparent volume of distribution, is defined as the theoretical volume 
in which the total amount of administered drug would need to be uniformly 
distributed to produce the desired blood concentration of a drug. Therefore higher Vd 
values indicate that the drug is more distributed in tissue. The volume of distribution 
at equilibrium (VSS) is used to calculate the drug amount in the body under steady-
state conditions, i.e. following drug i.v. infusion (Toutain and Bousquet-Melou 
2004). VSS after i.v. infusion differs only slightly from Vss after i.v. injection, 
therefore Vss was used to describe the volume of distribution in the conducted 
studies.  
The volume of distribution of mAbs is reported to be in the order of 0.1 L/kg which 
is approximately equal to the extracellular fluid volume (Mould and Green 2010). 
Antibodies are mainly distributed in the blood and extracellular fluid and not in 
tissues due to their size and hydrophobicity (Ternant and Paintaud 2005; Toutain and 
Bousquet-Melou 2004). Ustekinumab, mAb 8 and mAb 9 have VSS of about 0.1 L/kg 
(Table 4-11). This is in agreement with the VSS of other IgGs (Mould and Green 
2010). VSS of Briakinumab is higher which indicates a higher distribution in tissues 
or a faster cellular uptake. The bigger VSS can also be seen in the first hours of the 
concentration-time curves. To elucidate if Briakinumab shows higher unspecific 
binding to cell surfaces or has a faster cellular uptake, the working group of Dr. Olaf 
Mundigl (LMR Discovery, Roche Diagnostics GmbH, Mannheim, Germany, Site 
Penzberg) studied the uptake of Briakinumab and Ustekinumab in HeLa
FcRn
 cells 
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(The following findings were described by personal communication.). HeLa
FcRn
 cells 
are human epithelial cells of the cervical cancer that are transfected with human 
FcRn (Zhu et al. 2001). Briefly, Briakinumab and Ustekinumab were labeled with 
Alexa Fluor-488 and Alexa Fluor-594, respectively, according to the manufacturer’s 
instructions (Alexa Fluor® 488 and 594 Protein Labeling Kit, Life Technologies, 
USA). Afterwards labeled antibodies were incubated at a concentration of 5 µg/mL 
with HeLa
FcRn
 cells at pH 6.0 and studied using confocal microscopy (Leica SP5, 
Leica Microsystems, Germany). The cells were observed over a period of 
90 minutes. At the cell surface colocalisation of Briakinumab and Ustekinumab is 
observed indicating similar interactions with the cell membrane (Figure 5-1). 
Interestingly, the endosomes are divided in endosomes including only Briakinumab 
or only Ustekinumab. However, Briakinumab and Ustekinumab show similar 
interaction with the cell surface, therefore Briakinumab does not seem to have a 
faster cellular uptake due to positively charged regions in the Fv domain. 
 
 
 
 
 
 
Figure 5-1: HeLa
FcRn
 cells incubated with Briakinumab and Ustekinumab 
Confocal microscopy; (a) after 10 min and (b) after 25 min of incubation with Briakinumab 
(green) and Ustekinumab (red). Colocalisation is illustrated in yellow. 
The bigger VSS of Briakinumab could also be explained by the stronger interaction 
with mouse FcɣRI (Figure 4-14). Briakinumab’s stronger binding to mouse FcɣRI 
could lead to a faster decrease of serum concentrations due to faster uptake of 
Briakinumab into antigen-presenting cells, followed by faster elimination in the 
alpha phase. However, as mentioned in 5.2, this interaction needs to be studied with 
more appropriate tools to get stronger data. 
The area under the curve (AUC) represents the total drug exposure integrated over 
time and is an important parameter for both PK and PD analyses. The AUC is often 
(a) (b) 
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calculated from 0 hours to infinity (AUC0-inf). Distribution and elimination processes 
can influence the AUC. Therefore, Briakinumab has a lower AUC0-inf compared to 
Ustekinumab, mAb 8 and mAb 9 (Table 4-11) which is mainly caused by the fast 
serum concentration decrease within the first 24 hours.  
Clearance describes the volume of plasma cleared of the drug per unit time and 
therefore represents a proportionality factor between the elimination rate and the 
serum concentration. Antibodies do not undergo renal elimination or metabolism by 
hepatic enzymes such as cytochrome P450 due to their high molecular weights. They 
are mainly cleared via proteolytic catabolism (Mould and Green 2010; Tabrizi et al. 
2006).  
Antibodies raised against membrane-associated antigens exhibit non-linear clearance 
because it is influenced by a specific, saturable target-mediated pathway and a non-
specific linear clearance pathway mediated by the RES. The target-mediated 
clearance is dependent on several factors including the mAb-target affinity, the target 
concentration, distribution and internalization rate. High doses of antibody can 
saturate the target and reveal the linear clearance contribution (Mould and Green 
2010; Tabrizi et al. 2006; Wang et al. 2008). For this reason the administration dose 
is often > 1 mg/kg in PK studies, because antibodies often show linear clearance at 
these dose levels (Ling et al. 2009). 
In contrast, antibodies raised against soluble antigens, such as cytokines, generally 
exhibit dose-proportional, linear clearance after single-dose administration because 
clearance is only limited to catabolism (Lin et al. 1999; Tabrizi et al. 2006). The PK 
profile is characterized by a short distribution phase and a prolonged elimination 
half-life as a result of the non-specific clearance by the RES and the interaction with 
FcRn, respectively (Tabrizi et al. 2006). Antibodies bound to soluble antigens bind to 
FcRn and are internalized into cells, where antigen is degraded and intact antibody is 
recycled back to the circulation (Mould and Green 2010). When antibodies are 
administered at very high concentrations (2 g/kg), such as high-dose intravenous 
immunoglobin (IVIG), IgG half-lives are shortened attributed to saturation of the 
FcRn salvage pathway (Bleeker et al. 2001).  
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The antibodies investigated in this study are directed against IL-12, which represents 
a soluble target (Gandhi et al. 2010). The clearance is therefore influenced by a short 
distribution phase and a prolonged elimination half-life due to the interaction with 
FcRn. Briakinumab has a higher clearance compared to Ustekinumab, mAb 8 and 
mAb 9 which is mainly caused by the fast concentration decrease in the first 
24 hours. Zheng et al. (2012) have reported that antibodies with higher pI values 
(greater than ~9.0) tend to be associated with faster systemic clearance rates. Here, 
clearance did not correlate with the pI or the hydrophobicity or the charge calculated 
for the Fv domains which is in agreement with other reports (Hötzel et al. 2012). 
However, the focus of this work was to elucidate the influence of the Fv domain on 
FcRn-mediated IgG-recycling, therefore the terminal half-life was examined, which 
is exclusively calculated in the elimination phase where FcRn recycling dominates 
(Roopenian et al. 2010). 
The terminal half-life is defined as the period of time required for a drug serum 
concentration in the elimination phase to be reduced to half of its value. It describes 
only elimination processes and is therefore the best parameter to describe the 
influence of the mAb-FcRn interaction on PK. Briakinumab and Ustekinumab show 
terminal half-lives of 48 and 136 hours, respectively (Table 4-11). These differences 
are also observed in humans with terminal half-lives of Briakinumab and 
Ustekinumab of 8 and 22 days, respectively (Gandhi et al. 2010). Variants with 
smaller positively charged regions in the Fv domain have longer terminal half-lives 
than Briakinumab. Interestingly, the terminal half-lives of the four antibodies 
correlate linearly with the in vitro FcRn column elution pH (Figure 4-32). The higher 
the FcRn elution pH, the shorter is the terminal half-life in vivo. The correlation 
between terminal half-lives and the FcRn column elution pHs confirms the 
importance of efficient FcRn-IgG dissociation at physiological pH. A similar finding 
has been observed for Fc-engineered IgG molecules with improved FcRn binding at 
both endosomal pH 6.0 and at physiological pH 7.4 which did not show prolonged 
half-life (Yeung et al. 2009). The FcRn-IgG complex is built in the endosomes at 
pH 6.0, therefore, less binding results in less IgG-recycling and faster clearance. 
During exocytosis the FcRn-IgG complex is released to the plasma membrane, where 
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dissociation of IgG and FcRn has to occur at a physiological pH of 7.4 within a short 
period of time (Prabhat et al. 2007). Consequently, dissociation at physiological pH 
is also important for a prolonged half-life (Prabhat et al. 2007; Vaccaro et al. 2005). 
In conclusion, these findings support the assumption that antibodies showing slower 
dissociation at higher pH values are transported back into the cell and are 
subsequently degraded instead of being released back to blood circulation. 
The in vivo study in human FcRn knockout mice was conducted to confirm that 
differences in the terminal half-lives in human FcRn transgenic mice were caused by 
different FcRn-mAb interactions. The Three Rs (3Rs) describe guiding principles for 
a more ethical use of animals in research and comprise Replacement, Reduction and 
Refinement of test animals (Russell and Burch 1959). In order to reduce the animal 
number and follow the 3Rs guidelines only three antibodies conducted the knockout 
study: Briakinumab, Ustekinumab and mAb 9.  
After i.v. administration of 10 mg/kg antibody, the clearance of all antibodies is 
much faster in FcRn knockout mice than in human FcRn transgenic mice (Figure 
4-33) due to missing FcRn-mediated IgG-recycling (Junghans 1997; Roopenian et al. 
2003; Ternant and Paintaud 2005). Especially Briakinumab is eliminated very fast, 
thereby preventing clear division in alpha and beta phase. Consequently, calculation 
of the terminal half-life is (most likely) inaccurate due to a missing beta phase. 
Briakinumab has a different pharmacokinetic behavior with faster distribution in the 
first hours after administration compared to Ustekinumab and mAb 9. This finding 
was also observed in human FcRn transgenic mice which indicates that the 
distribution processes in the first hours after administration is not FcRn-mediated. 
Ustekinumab and mAb 9 have nearly identical terminal half-lives indicating that 
half-life differences in human FcRn transgenic mice were FcRn-mediated (Table 
4-13). The study could have been improved if the sample collection time points were 
modified. Sample collections after 3 and 4 days would lead to a more precise 
terminal half-life calculation of Ustekinumab and mAb 9. Furthermore including 
mAb 8 into the study would be reasonable. MAb 8 shows the same distribution 
behavior in the alpha phase as Ustekinumab and mAb 9 and could therefore show the 
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same PK profile as Ustekinumab and mAb 9 in FcRn knockout mice. MAb 8 could 
consequently confirm that half-life differences in FcRn transgenic mice were FcRn-
mediated because the terminal half-life difference between mAb 8 and Ustekinumab 
was even bigger than between Ustekinumab and mAb 9. 
Immunogenic reactions can also influence blood levels by binding to the antibody 
(van Beers et al. 2010) that can be seen in a rapid decrease of the concentration-time 
curves after about six days (Roopenian et al. 2010) Immunogenicity is the ability to 
provoke an immune response. In the course of an immune response anti-drug 
antibodies (ADAs) can occur which can influence pharmacokinetics, efficacy and/or 
induce allergic reactions. ADAs can be classified in neutralizing antibodies and in 
binding (or non-neutralizing) antibodies (Casadevall et al. 2002). Neutralizing 
antibodies bind to the active site of the therapeutic protein and thereby inhibit its 
function resulting in diminished efficacy (Brinks et al. 2011; Putnam et al. 2010). 
Binding antibodies bind to the therapeutic protein and may change its PK but do not 
affect its intrinsic activity. Binding antibodies can result in faster clearance which 
can be recognized by a sharp bend in the concentration-time curve. There are factors 
advancing ADA development, like using antibodies of a different species (murine 
mAbs in human and vice versa) or multiple dose s.c. administration in contrast to 
single dose i.v. administration (Bertolotti-Ciarlet et al. 2009; Perini et al. 2001). 
In both studies, after single dose i.v. administration of Briakinumab, mAb 8 and 
mAb 9 drug-ADA immune-complexes were detected (Table 4-12 and Table 4-14). 
The drug-ADA complexes were detected after about 7-14 days. The antibodies used 
in the studies were human antibodies, therefore the murine immune system identified 
the foreign antibodies and produced ADAs. The appearance of ADAs cannot be seen 
in the concentration-time curve. For example, Ustekinumab and mAb 9 have very 
similar concentration-time curves in the FcRn knockout study (Figure 4-33), 
although only after administration of mAb 9 ADAs can be detected. Therefore the 
influence of these ADAs on PK is expected to be negligible. It is not understood why 
Ustekinumab did not induce ADA formation, but it would be interesting to study this 
phenomenon. 
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5.5. Transferability to other mAbs 
The Briakinumab-Ustekinumab model system showed that charged regions in the Fv 
domain, especially in the VL domain, influence FcRn-IgG dissociation. A second 
model antibody system was used to show the transferability of these findings. 
Bevacizumab was chosen because the charge distribution showed no striking 
positively or negatively charged regions in the Fv domain and the terminal half-life is 
reported to be about 21 days. Bevacizumab was modified by mutation of three amino 
acids in the VL domain into basic amino acids resulting in a Bevacizumab-variant 
that possessed a larger positively charged region in the VL domain compared to the 
wild type (Figure 4-36). As expected, the Bevacizumab-variant eluted at a higher pH 
from the FcRn column than Bevacizumab (Figure 4-38). Therefore positively 
charged regions in the VL domain resulted in FcRn-IgG dissociation at higher pH 
values for both model systems. The retention time shift was considered to be too 
small to result in statistically significant different terminal half-lives in vivo. 
Therefore this antibody pair was not tested in an in vivo PK study. The retention time 
shift could probably be further increased by enlarging the positively charged region 
all over the Fv domain which could then justify an in vivo study. 
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5.6. FcRn affinity column as analytical tool 
FcRn plays a key role in regulating IgG homeostasis (Ghetie and Ward 2000), 
therefore analyzing the FcRn-IgG interaction is essential in predicting PK in drug 
development. The FcRn-IgG interaction consists of two parts that need to be 
analyzed separately: Binding at pH 6.0 and dissociation at higher pH values. 
The FcRn affinity chromatography closely mimics physiological conditions for the 
dissociation of the FcRn-IgG complex. This method was shown to be a sensitive tool 
for analyzing differences in FcRn-IgG dissociation (Schlothauer et al. 2013). 
Structural differences in the Fab region and modified charged regions in the Fv 
domain resulted in altered FcRn column retention times. Furthermore, it is possible 
to separate species based on their FcRn binding properties using FcRn affinity 
chromatography.  
Charge-mediated FcRn-IgG interactions can be precisely analyzed using two 
different methods; the FcRn affinity chromatography under high ionic strength 
conditions and the FcRn affinity chromatography using a salt gradient. The salt 
gradient FcRn affinity chromatography allows to analyze the influence of charged 
regions in the Fab within a single run. 
In this work, the in vitro FcRn column elution pHs correlate linearly with the 
terminal half-lives of the four antibodies, thereby indicating the potential of FcRn 
affinity chromatography to predict Fab-mediated PK properties. Retention time shifts 
of ≥ 4 minutes resulted in statistically different terminal half-lives.  
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6. Final summary and conclusions 
The general aim of this thesis was to elucidate the influence of the Fab region on 
interactions with FcRn as well as on FcRn-dependent pharmacokinetics. FcRn 
protects IgG from degradation and is responsible for the long half-life of IgG. 
Modulating the interaction between IgG and FcRn through protein engineering is an 
attractive method for modulating the PK of therapeutic antibodies. Modifications in 
the Fc region are known to affect FcRn-IgG interaction and a contribution of the Fab 
region has been reported. However, the underlying mechanism how the distal Fab 
region influences FcRn binding was hitherto only poorly understood.  
To elucidate the influence of the Fab region on FcRn-IgG interactions, two IgG1 
antibodies Briakinumab and Ustekinumab that have similar Fc regions but different 
terminal half-lives in human were used as a model system. Systematically engineered 
variants of both antibodies with cross-over exchanges and modified charge 
distributions were produced to investigate the influencing structural element of the 
Fab region and the mechanism that influences FcRn-IgG interactions. 
Briefly, the work was divided in 5 parts. In part 1 and 2 the antibodies were 
biochemically and functionally characterized to test that antibodies were produced 
correctly and to find possible reasons explaining PK differences of Briakinumab and 
Ustekinumab. The third part analyzed the FcRn-IgG interaction to study if PK 
differences can be mediated by this interaction. Afterwards, in part 4, the effect of 
different FcRn-IgG dissociations on in vivo PK was investigated. Finally, the 
transferability of the previous results to a second model system was analyzed. 
In Part 1 the produced antibodies were biochemical characterized. Antibody size and 
molecular weight were in agreement with other IgG1 antibodies, therefore it was 
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concluded that all antibodies were produced correctly. Both antibodies were resistant 
to freeze-thaw and storage-temperature stress indicating high protein stability and a 
low tendency for protein aggregation. Furthermore, antibody net charges and 
hydrophobicity were in a narrow range for Briakinumab and Ustekinumab, which 
minimizes the occurrence of different absorption/unspecific binding processes. It was 
concluded that biochemical properties of Briakinumab, Ustekinumab and the variants 
cannot result in major PK differences.  
Part 2 describes the functional characterization of the antibodies which includes 
affinity to the target (human IL-12 and IL-23) and affinity to mouse target (mouse 
IL-12 and mouse IL-23). Briakinumab, Ustekinumab and the variants, except 
variants with exchanged LCs and CDRs, bind their target with high affinity. 
Therefore, Briakinumab, Ustekinumab, variants with exchanged Fv domains and 
variants with modified charge distributions were still functional intact. Furthermore, 
it was confirmed that the four antibodies studied later in in vivo experiments were not 
cross-reactive to the mouse target and consequently target-mediated clearance effects 
could be excluded when performing an in vivo mouse study. Taken together, 
antibodies were functional intact except for antibodies with exchanged LCs or CDRs. 
Antibodies that conducted the PK studies showed high affinity to human IL-12 and 
no cross-reactivity to mouse IL-12/IL-23, therefore it was concluded that these 
antibodies should not show target-mediated clearance effects.  
The in vitro interaction between FcRn and the antibodies was analyzed in Part 3. To 
gain a prolonged half-life due to FcRn-mediated IgG recycling, an antibody needs to 
have a strong affinity at endosomal pH of 6.0 and a fast dissociation at physiological 
pH of 7.4. Any deviation of this strict, pH-dependent bind-and-release mechanism is 
critical for IgG-recycling. Antibodies showed only slight differences in pH 6.0 
affinity, therefore the Fab region seems to have negligible influence on pH 6.0 
binding. In contrast, the dissociation between FcRn and the antibodies was strongly 
influenced by the Fab region. 
Analysis of the cross-over variants revealed that the Fv domain, especially the VL 
domain provides a slower-than-normal dissociation. Using the variants with modified 
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charge distribution, FcRn affinity chromatography under high ionic strength 
conditions and salt-gradient FcRn affinity chromatography, it was shown that the 
interaction between FcRn and Fv domain was charge-mediated. In addition, 
molecular dynamics simulations of the FcRn-IgG complexes demonstrated that the 
flexibility of the Fab arms structurally allows a direct, stabilizing interaction of the 
Fv domain with the tip of FcRn. To sum up, the charge distribution in the Fv domain, 
especially in the VL domain of an antibody influences the FcRn-IgG dissociation. 
More positively charged regions in the Fv domain resulted in FcRn dissociation at 
higher pH values.  
In Part 4 the influence of different FcRn-IgG dissociations on FcRn-dependent PK 
was analyzed. Therefore four antibodies (Briakinumab, Ustekinumab, mAb 8 and 
mAb 9) conducted a PK study in human FcRn transgenic and in FcRn knockout 
mice. The best PK parameter to describe differences in FcRn-mediated IgG-recycling 
is the terminal half-life. Dissociation of antibodies at higher pH values resulted in 
reduced terminal half-lives in human FcRn transgenic mice. More precisely, FcRn-
IgG dissociation pHs in vitro correlated linearly with in vivo terminal half-lives. In 
conclusion, these findings support the assumption that antibodies showing slower 
dissociation at higher pH values are transported back into the cell and are 
subsequently degraded instead of being released back to blood circulation. 
In FcRn knockout mice the terminal half-lives were smaller due to missing FcRn-
mediated IgG-recycling. The terminal half-lives of Ustekinumab and mAb 9 were 
identical indicating that differences in human FcRn transgenic mice were FcRn-
mediated. Briakinumab showed a much faster clearance in the first hours after 
administration in both mice types probably due to different distribution processes. 
However, the terminal half-life was calculated in the elimination phase and was not 
affected by different distribution processes.  
Taken together, larger positively charge regions in the Fv domain are involved in 
FcRn-IgG dissociation at increased pH values. This slower-than-normal dissociation 
prevents efficient FcRn-IgG dissociation at physiological pH, thereby reducing 
FcRn-dependent terminal half-lives.  
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It remained unknown if charged regions in the Fv domain influence FcRn-IgG 
interaction in general. Therefore, in Part 5, the transferability of the previous results 
was tested. Bevacizumab was used as second antibody because the charge 
distribution showed no striking positively or negatively charged regions in the Fv 
domain. A Bevacizumab-variant was produced that exhibited an additional positively 
charged region in the VL domain. Bevacizumab-variant had a slower dissociation 
from the FcRn than Bevacizumab. In conclusion, positively charged regions in the 
VL domain resulted in FcRn-IgG dissociation at higher pH values for both model 
systems. 
Taken together conclusions from all chapters it was demonstrated that the charge 
distribution in the Fv domain of IgGs is involved in excessive binding to FcRn, 
thereby reducing FcRn-dependent terminal half-lives in vivo. These findings 
contribute to a better understanding of the FcRn-IgG interaction and it could also 
provide profound potential in FcRn-dependent antibody-engineering of the variable 
Fab region. For example, in drug development the interaction of FcRn and antibody 
needs to be analyzed in two separate steps to predict PK behavior as best as possible: 
pH affinity at pH 6.0 and the dissociation profile at higher pH values. Antibodies that 
show a slower-than-normal dissociation could be analyzed and screened for 
positively charged regions in the Fv domain. To increase FcRn-IgG dissociation and 
thereby most likely improve antibody PK of these antibodies it should be considered 
to choose an antibody variant that exhibits smaller positively charged regions in the 
Fv domain. Furthermore FcRn affinity chromatography can be used to identify 
candidates at risk for poor PK properties with reduced terminal half-lives. The 
findings of this work contribute to a better understanding of the FcRn-IgG interaction 
and might allow to “repair” such candidates. 
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7. Addendum 
7.1. Tables 
Table 7-1: Serum concentrations of Briakinumab in huFcRn transgenic mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group. ADA-positive samples are illustrated as * and ** for 
formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 201 174 188 192 214 194 194 13 
2 109 105 106 105 110 110 107 2.4 
8 50 53 53 54 56 58 54 2.8 
24/ 1 37 32 30 34 35 35 34 2.4 
48/ 2 27 23 24 27 24 28 25 2.2 
168/ 7 6.2 5.4 6.7 6.7 * 6.4 6.8 6.4 0.5 
336/ 14 0.4 1.0 * 0.1 ** 0.2 ** 0.7 * 0.1 ** 0.4 0.4 
504/ 21 b.l.q. b.l.q.*
* 
b.l.q.*
* 
b.l.q.*
* 
b.l.q.*
* 
b.l.q.*
* 
b.l.q. - 
672/ 28 b.l.q. b.l.q.*
* 
b.l.q. b.l.q.*
* 
b.l.q.*
* 
b.l.q.*
* 
b.l.q. - 
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Table 7-2: Serum concentrations of Ustekinumab in huFcRn transgenic mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group. ADA-positive samples are illustrated as * and ** for 
formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 205 219 212 225 202 226 215 10 
2 156 161 191 175 153 215 175 24 
8 120 116 110 114 114 115 115 3.2 
24/ 1 73 77 72 73* 69 76 73 2.9 
48/ 2 58 57 64 57 56 59 59 2.7 
168/ 7 18 19 27 22 20 25 22 3.5 
336/ 14 7.2 6.8 8.0 6.2 8.3 4.8 6.9 1.3 
504/ 21 2.2 2.2 2.5 2.3 2.5 3.0 * 2.5 0.3 
672/ 28 0.9 0.8 2.1 1.1 1.0 1.8 1.3 0.5 
 
Table 7-3: Serum concentrations of mAb 8 in huFcRn transgenic mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group. ADA-positive samples are illustrated as * and ** for 
formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 241 177 174 203 220 217 206 26 
2 146 175 155 120 109 146 142 24 
8 90 95 97 106 108 85 97 8.7 
24/ 1 76 55 55 59 80 72 66 10.9 
48/ 2 65 52 56 71 71 68 64 8.1 
168/ 7 24 28 25 28 27 21 ** 25 2.6 
336/ 14 7.7 2.9 * 4.4 1.3 * 2.4 ** 6.7 * 4.2 2.5 
504/ 21 3.1 0.1 ** 2.3 2.1 0.1 ** 0.1 1.3 1.4 
672/ 28 b.l.q. 
** 
b.l.q. 
** 
b.l.q. 
** 
b.l.q. 
** 
b.l.q. * b.l.q. 
** 
b.l.q. - 
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Table 7-4: Serum concentrations of mAb 9 in huFcRn transgenic mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group. ADA-positive samples are illustrated as * and ** for 
formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 194 254 198 270 295 233 241 40 
2 151 183 124 143 165 137 150 21 
8 126 104 109 89 111 114 109 12 
24/ 1 73 80 64 89 94 77 80 11 
48/ 2 65 81 66 69 83 60 71 9.2 
168/ 7 34 37 31 30 * 38 36 34 3.1 
336/ 14 13 15 ** 14 ** 15 ** 13 ** 9.6 ** 13 1.9 
504/ 21 4.2 0.3 ** 4.5 * 4.9 ** 0.1 ** 4.8 ** 3.1 2.3 
672/ 28 0.1 ** 2.4 * 1.4 * 1.5 * 2.5 0.1 * 1.3 1.1 
 
Table 7-5: Serum concentrations of Briakinumab in FcRn knockout mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group. ADA-positive samples are illustrated as * and ** for 
formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 192 181 200 187 186 178 187 8.0 
2 86 79 74 91 89 91 85 7.1 
8 31 32 36 31 29 33 32 2.3 
24/ 1 6.7 12 7.9 11 6.9 8.0 8.7 2.1 
48/ 2 1.8 2.3 2.7 2.6 2.4 2.2 2.3 0.3 
168/ 7 b.l.q. b.l.q. b.l.q. 
** 
b.l.q. b.l.q. 
** 
b.l.q. b.l.q. - 
192/ 8 b.l.q. * b.l.q. * b.l.q. 
** 
b.l.q. * b.l.q. 
** 
b.l.q. 
** 
b.l.q. - 
216/ 9 b.l.q. * b.l.q. b.l.q. 
** 
b.l.q. 
** 
b.l.q. * b.l.q.*
* 
b.l.q. - 
336/ 14 b.l.q. b.l.q. 
** 
b.l.q. * b.l.q. 
** 
b.l.q. 
** 
b.l.q. * b.l.q. - 
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Table 7-6: Serum concentrations of Ustekinumab in FcRn knockout mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group.  
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 209 221 229 228 220 219 221 7.4 
2 153 164 158 155 157 149 156 4.8 
8 80 95 88 96 104 95 93 8.0 
24/ 1 50 47 37 44 38 37 42 5.5 
48/ 2 16 16 17 13 11 14 15 2.2 
168/ 7 0.4 0.6 0.4 0.3 0.6 0.4 0.5 0.1 
192/ 8 0.5 0.2 0.1 0.1 0.2 0.4 0.2 0.2 
216/ 9 b.l.q. b.l.q. b.l.q. b.l.q. b.l.q. b.l.q. b.l.q. - 
336/ 14 b.l.q. b.l.q. b.l.q. b.l.q. b.l.q. b.l.q. b.l.q. - 
 
Table 7-7: Serum concentrations of mAb 9 in FcRn knockout mice 
Serum concentrations are determined after administration of a 10 mg/kg single dose i.v. 
injection to 6 animals per group. ADA-positive samples are illustrated as * and ** for 
formation of moderate and severe drug/ADA immune complexes, respectively. 
Time  
[h/d] 
M 1 
[µg/mL] 
M 2 
[µg/mL] 
M 3 
[µg/mL] 
M 4 
[µg/mL] 
M 5 
[µg/mL] 
M 6 
[µg/mL] 
Mean 
[µg/mL] 
SD 
[µg/mL] 
0.08 249 292 232 214 242 226 242 27 
2 119 130 139 136 123 129 129 7.3 
8 62 65 74 80 83 87 75 10 
24/ 1 31 37 37 32 35 36 35 2.6 
48/ 2 16 15 17 12 13 16 15 1.9 
168/ 7 0.2 * 0.4 ** 0.5 0.5 0.5 0.3 0.4 0.1 
192/ 8 0.2 0.1 ** 0.2 0.1 ** 0.1 ** 0.2 0.2 0.2 
216/ 9 b.l.q. b.l.q. 
** 
b.l.q. 
** 
b.l.q. b.l.q. 
* 
b.l.q. 
** 
b.l.q. - 
336/ 14 b.l.q. 
* 
b.l.q. 
** 
b.l.q. b.l.q. b.l.q. 
* 
b.l.q. b.l.q. - 
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7.2. List of abbreviations 
ABTS  2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
ACS  American chemical society 
ADA  Anti-drug antibody 
AUC0-inf Area under the curve (0 h- infinity) 
Bi  Biotin 
B.l.q.  Below limit of quantification 
β2m  Beta-2-microglobulin 
c  Concentration 
CDR  Complementarity determining region 
Cl  Clearance 
Da  Dalton 
Dig  Digoxigenin 
DTT  Dithiothreitol 
ELISA  Enzyme-linked immunosorbent assay 
Fab  Fragment antigen-binding 
Fc  Fragment crystallizable  
FcɣR  Fc gamma receptor 
FcRn  Neonatal Fc receptor 
Fig  Figure 
Fv  Variable fragment 
h  Hour 
List of abbreviations 
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huFcRn Human neonatal Fc receptor 
hIL  Human interleukin 
His  Histidine 
HMWs Higher molecular weight species 
HPLC  High liquid perfomance chromatography 
HRP  Horseradish peroxidase 
Id  Idiotype 
IdeS  Immunoglobulin-degrading enzyme from Streptococcus pyogenes 
IEC  Ion exchange chromatography 
Ig  Immunoglobulin 
IL  Interleukin 
i.v.  Intravenously 
ka  Association rate constant 
kd  Dissociation rate constant 
KD  Equilibrium dissociation constant 
LMWs  Lower molecular weight species 
M  Molar 
mAb  Monoclonal antibody 
MACE Major adverse cardiovascular event 
MES  2-(N-morpholine)-ethanesulfonic acid  
mg  Milligram 
MHC  Major histocompatibility complex 
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min  Minute 
ml  Milliliter 
MPS  Mouse Pool Serum 
MS  Mass spectrometry 
MTP  Microtiter plate 
muFcɣR  Murine Fc gamma receptor 
muFcRn Murine neonatal Fc receptor 
muIL  Murine interleukin 
ng  Nanogram 
nM  Nanomolar 
OD  Optical density 
PBS  Phosphate buffered saline 
Ph.Eur. European pharmocopeia 
pI  Isoelectric point 
PK  Pharmacokinetics 
POD  Peroxidase 
PUVA  Psoralen ultraviolet A 
QC  Quality control 
RES  Reticuloendothelial System 
RP-HPLC Reverse phase HPLC 
rpm  rounds per minute 
R  Correlation coefficient 
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RT  Room temperature (15-25°C) 
RU  Response unit 
SA  Streptavidin 
s.c.  subcutanously 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC  Size exclusion chromatography 
SPR  Surface plasmon resonance 
T1/2  Terminal half-life 
TRIS  Tris(hydroxymethyl)aminomethane 
U  Unit 
UV  Ultraviolet 
VEGF  Vascular endothelial growth factor 
VSS  Volume of distribution at Steady-State 
WT  Wild type 
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